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ABSTRACT
Lung transplantation is the only eff ective treatment for selected patients with end-stage lung 
diseases and limited life expectancy and poor quality of life. Chronic lung allograft  dysfunction 
(CLAD) is the major life-limiting factor aft er lung transplantation and bronchiolitis obliterans 
syndrome (BOS) is the most common subtype and best-characterized form of CLAD. BOS is a 
clinical diagnosis and it is defi ned as deterioration of lung allograft  function in the absence of 
any other identifi able cause. Pathologically, BOS presents as obliterative bronchiolitis (OB) and 
it is characterized by peribronchial infl ammation, epithelial damage, and obliteration of small 
and medium-sized bronchioli by fi brotic plaques. BOS is the leading cause of morbidity, lung 
allograft  loss, and mortality aft er the fi rst post-operative year. No specifi c treatment is available 
for clinical BOS at the moment.
Perioperative injury of the lung allograft  leads to the activation of an immediate innate immunity 
response. Innate immunity plays a crucial role in the modulation of adaptive immunity. 
Activation of adaptive immunity responses results in acute rejection of the allograft . Repetitive 
rejection episodes are the best characterized risk factor for BOS. At present, immunosuppressive 
treatment mainly focuses on suppressing the adaptive immunity and this appears to be inadequate 
to prevent BOS. In this study, we hypothesized that inhibiting innate immune activation through 
diff erent pathways infl uences the development of experimental OB. To test our hypothesis, we 
investigated diff erent factors and pathways leading to experimental OB using both rat and mouse 
heterotopic tracheal allograft  models.
In these models, the donor trachea is excised and transplanted into the subcutaneous pouch of 
the mouse or into the greater omentum of the recipient rat. Th ere is a severe ischemic phase 
in the tracheal graft  aft er transplantation before tracheal neo-vascularization develops. In this 
study, both the syngraft s and allograft s showed severe epithelial injury and innate immune 
activation early aft er transplantation.  It is likely that lack of alloantigens led to the resolution 
of the infl ammatory response through activation of dominant  tolerogenic T cells in syngraft s. 
Th e absence of alloimmune activation resulted in regeneration of the tracheal epithelium and 
the tracheal lumen remained completely open. However, in the presence of alloantigens, early 
ischemic injury induced both innate and adaptive immune responses followed by Th 17 activation 
and aft erwards by a sustained Th 1 immune response. Th is was accompanied by infi ltration of 
the allograft  with proinfl ammatory eff ector cells that target the tracheal epithelium and lead 
to progressive fi broproliferation and total tracheal occlusion. Interestingly, recipient treatment 
with simvastatin, a cholesterol-lowering drug with lipid-independent immunomodulatory 
properties, enhanced early epithelial recovery aft er transplantation in the allograft s. It also 
inhibited the infi ltration of infl ammatory cells and the expression of lymphocyte chemokines 
and proinfl ammatory cytokine mRNA. Most importantly, simvastatin inhibited the development 
of experimental OB in the absence of other immunosuppression. 
Th e cellular responses to hypoxia are regulated by transcription factors called hypoxia inducible 
factors (HIFs). HIF-1 is a principle regulator of hypoxic adaptation, regulating gene expression 
involved in glycolysis, erythropoiesis, angiogenesis, proliferation, and stem cell function under 
hypoxia. In addition, HIF-1 plays an important role in infl ammatory responses of myeloid cells 
but these eff ects may be either pro- or anti-infl ammatory depending on the setting. In this study, 
we used the heterotopic mouse tracheal allograft  model and fully major histocompatibility 
complex (MHC) mismatched recipients to investigate the eff ect of myeloid cell-targeted gene 
deletion of HIF-1α or its negative regulator pVHL in the recipients of tracheal allograft s on the 
development of experimental OB. We found that continuous HIF-1 expression in myeloid cells 
improved epithelial recovery, reduced infl ammatory cell accumulation, and increased regulatory 
FoxP3 mRNA expression in mouse tracheal allograft s. Importantly, these eff ects led to better 
preservation of tracheal epithelium and a decrease in the development of experimental OB 
suggesting a protective role of HIF-1 in this constellation.
Th e results of this study suggest that the early ischemic injury and the following innate immune 
response play major roles in the development of OB. Th e role of statins should also be thoroughly 
evaluated in the treatment of lung transplant patients. In addition, it seems that despite the 
shortcomings of the murine heterotopic allograft  model many advantageous features favour its 
use in OB investigation also in the future, until a signifi cantly better method is present ed.
1INTRODUCTION
Lung transplantation (LT) is the only eff ective treatment for selected patients with end-stage lung 
diseases and limited life expectancy and poor quality of life. Chronic lung allograft  dysfunction 
(CLAD) is a major life-limiting factor aft er lung transplantation. Th is review concentrates on 
the bronchiolitis obliterans syndrome (BOS), which is the most common subtype and best-
characterized form of CLAD. BOS is a clinical diagnosis and it is defi ned as a deterioration of 
lung allograft  function in the absence of any other identifi able cause, such as acute rejection, 
infection, or anastomotic complication (Estenne et al. 2001). According to the International 
Society for Heart and Lung Transplantation (ISHLT), the diagnosis of BOS requires a permanent 
20% decrease in forced expiratory volume in one second (FEV1) in spirometry compared to 
stable post-transplant baseline values (Cooper et al. 1993, Estenne et al. 2001). However, it is 
still quite diffi  cult to diagnose BOS reliably even with modern techniques. Pathologically, BOS 
presents as obliterative bronchiolitis (OB) and it is characterized by peribronchial infl ammation, 
epithelial damage, and obliteration of small and medium-sized bronchioli by fi brotic plaques 
(Yousem et al. 1996).  
Although the results of lung transplantation have markedly improved during recent decades, 
there are still major unsolved problems considering BOS. BOS is the leading cause of morbidity, 
lung allograft  loss, and mortality aft er the fi rst post-operative year (Yusen et al. 2013). Even with 
modern immunosuppressive treatment almost 50% of the recipients developed  BOS fi ve years 
aft er transplantation and within 10 years the percentage is still 76% (Yusen et al. 2013). Present 
immunosuppressive treatment modalities mainly concentrate on suppressing the adaptive 
immunity, especially T cell function and this appears to be inadequate. Th ere is no specifi c 
treatment for OB/BOS and the exact etiology and pathogenesis of OB are not yet fully elucidated. 
Th e perioperative period is associated with signifi cant immune activation. A cytokine storm 
following donor brain death, donor infection, and possible aspiration episodes all contribute 
to the development of lung allograft  injury. In addition, cold and warm ischemia during the 
preservation, transportation, and implantation of the lung transplant may enhance the injury 
(Christie, Kotloff  et al. 2005; Daud et al. 2007). Th ese events lead to the activation of an immediate 
innate immunity response. Innate immunity plays a crucial role in the modulation of adaptive 
immunity as it precedes and prepares the ground for  adaptive immunity responses (Palmer et 
al. 2003, Land 2007). Activation of adaptive immunity responses causes acute rejection of the 
allograft . Repetitive rejection episodes might eventually lead to the development of BOS (Estenne 
et al. 2002, Hopkins et al. 2004).
We hypothesized that innate immune activation plays a central role in the development of OB. 
Using rat and mouse heterotopic tracheal allograft  models, we investigated whether inhibition 
of innate immune activation through diff erent pathways could infl uence the development of 
experimental OB. A special emphasis was placed on the heterotopic tracheal allograft  model 
itself, innate immune response, the role of simvastatin treatment, and HIF-1- expression.
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2REVIEW OF THE LITERATURE
1.  Chronic lung allograŌ  dysfuncƟ on
Chronic lung allograft  dysfunction (CLAD) is a term for all cases of chronic deterioration of 
lung allograft  function (Verdeleden 2014). Previously bronchiolitis obliterans syndrome (BOS) 
was considered the only form of CLAD, but several new subtypes of CLAD have been identifi ed 
during the recent years (Sato et al. 2011). Th ese include neutrophilic reversible allograft 
dysfunction (NRAD), fi brous BOS, and restrictive allograft  syndrome (RAS) (Verleden et 
al. 2014, Sato et al. 2011). Patients with NRAD have neutrophilia in the airways, which may 
respond to azithromycin therapy (Verleden et al.  2013). On the other hand, patients with BOS 
have less infl ammation and more fi brosis in the airways and due to this there is no response to 
azithromycin or other immunosuppressive treatment (Sato 2013). RAS is defi ned as a fi brotic 
process in lung parenchyma and produces more aggressive functional decline than conventional 
BOS (Verleden et al. 2014, Sato et al. 2011). Th e RAS phenotype of CLAD is considered when a 
patient shows an irreversible decline in lung capacity and meets certain criteria: FEV1 should be 
< 80% and total lung capacity (TLC) should be < 90% of the post transplant baseline values in 
spirometry (Sato et al. 2011). However, defi nition and diagnostic criteria of all CLAD subtypes 
are not yet fully established and universally accepted (Woodrow et al. 2010). A precise defi nition 
of CLAD is also to be determined (Meyer et al. 2014) and further investigation of the mechanisms 
and risk factors of the development of CLAD subtypes is needed. Th is review concentrates on 
BOS as it is the best-characterized form of CLAD and the experimental models we used were 
developed to study BOS.
2.  Clinical lung transplantaƟ on
Th e fi rst experimental lung transplantations (LT) were performed in the 1940s and 1950s, but 
the fi rst human LT was performed by Dr. James Hardy and his surgical team at the University 
of Mississippi in 1963 (Hardy et al. 1963). However, early results were poor and post-operative 
mortality was universal due to surgical complications and lack of effi  cient immunosuppressive 
drugs. Th ese problems resulted in a decline in lung transplantation activity until a proper 
immunosuppressive drug, cyclosporine A, was introduced. Dr. Cooper and his team performed 
the fi rst successful single (1983) and double (1985) LT at the University of Toronto, Canada 
(Cooper et al. 1989). Together with improvements in the treatment of rejection, donor care, 
surgical techniques, intensive and other postoperative care, and antimicrobial therapy, LT 
was established as routine treatment for end-stage pulmonary diseases in the late 1980`s 
(Higenbottam et al. 1990).
2.1.  Indica? ons for lung transplanta? on in adults
According to the recent ISHLT Consensus document, patients who have chronic, end-stage lung 
disease and are considered for lung transplant operation should meet the criteria shown in Table 
1. (Weill et al. 2015):
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3Table 1. General criteria for adult lung transplantation according to the ISHLT Consensus Document 
(modifi ed from Weill et al. 2015)
>50% risk of death from lung disease within 2 years without transplant operation
>80% chance to survive at least 3 months aft er operation
>80% likehood of 5-year survival aft er operation with adequate graft  function
Usually, these patients are not amenable for medical treatment or conservative surgical/
endoscopical treatment, i.e., endobronchial valve replacement or lung volume reduction surgery. 
Th e main goal of LT is to provide survival benefi t. However, this treatment also signifi cantly 
improves the quality of life of these patients. According to recent studies, especially physical health 
and every day functioning of the lung transplant patients is improved signifi cantly during the 
fi rst postoperative year and their physical quality of life is comparable to healthy population one 
year aft er the operation (Copeland et al. 2013; Singer et al. 2013). Unfortunately, psychological 
wellbeing of these patients may remain abnormal despite the operation (Copeland et al. 2013). 
Th e main indications for adult LT are listed in Table 2. Two thirds of lung transplant recipients 
are 45 - 65 years old (Yusen et al. 2013). In the past 30 years, the median age of recipients has 
increased from 45 to 55 years. Only 10% of the recipients were over 65 and 3 % over 70 years old 
(Yusen et al. 2013).  
Table 2. Indications for adult primary lung transplantation performed 1995-2012. Data from the 
Registry of the ISHLT 30th report (modifi ed from Yusen et al. 2013) 
Chronic obstructive pulmonary disease (COPD) 34%
Interstial lung diseases (ILD) 24%
Bronchiectasis associated with cystic fi brosis (CF) 17%
a1-antitripsin defi ciency emphysema 6%
Idiopathic pulmonary artery hypertension (PAH) 2% 
Others 17%
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2.2.  Contraindica? ons for lung transplanta? on in adults
Th ere are several absolute contraindications for LT and these are shown in Table 3. 
Table 3. Absolute contraindications for lung transplantation according to the ISHLT Consensus 
Document (modifi ed from Weill et al. 2015)
Untreatable other major organ dysfunction (e.g. heart, liver, kidney and brain) unless combined 
organ transplantation can be performed
Active malignancy in the last 5 years (except non-melanoma carcinoma of skin)
Uncorrected atherosclerotic disease with end-organ ischemia or dysfunction
Coronary artery disease not amenable to revascularization
Acute medical instability (e.g. sepsis, myocardial infarction, liver failure)
Uncorrectable bleeding diathesis
Chronic infection with highly virulent and/or resistant microbes
Evidence of active Mycobacterium tuberculosis infection
Severe chest wall or spinal deformity
Body mass index > 35,0
Non-adherence to medical therapy (current or prolonged episodes)
Absence of an adequate social support system
Severely limited functional status with poor rehabilitation potential
Substance abuse or dependence (e.g. alcohol, tobacco, marijuana etc.)
Psychiatric or cognitive conditions associated with limited co-operation
Th ere are also several relative contraindications for LT, such as age. Th ere is basically no absolute 
age limit for lung transplantation and an operation may be considered for highly selected 
patients older than 65 years with no other severe comorbidities. However, patients > 75 years 
are unlikely to benefi t from the operation in most cases (Weill et al. 2015).  Chronic medical 
conditions without end-organ failure are not contraindications for transplantation (e.g. hepatitis 
B/C, HIV, diabetes mellitus), but these patients should be operated in centers with expertise in 
care of these patients (Weill et al. 2015). Other relative contraindications for lung transplantation 
are shown in Table 4.  
Table 4. Relative contraindications for lung transplantation according to the ISHLT Consensus 
Document (modifi ed from Weill et al. 2015)
Age > 75 years (age > 65 years and associated low physiologic reserve and/or other relative 
contraindications)
Body mass index 30.0 -34.9
Progressive or severe malnutrition
Severe symptomatic osteoporosis
Extensive prior chest surgery with lung resection
Mechanical ventilation
Chronic extrapulmonary infection expected to worsen aft er transplantation
Atherosclerotic disease with the risk of end-organ disease aft er lung transplantation
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2.3.  Survival of lung transplant recipients
Th e ISHLT Registry contains data of over 47 000 adult lung transplants that were performed by 
June 30 2013 (Yusen et al. 2014). Although survival aft er LT has improved over the past 25 years, 
long-term survival remains a challenge. In the latest ISHLT report from 1994 – 2011, the median 
survival was 5.6 years and survival at 1, 5, and 10 years was 79%, 53%, and 31%, respectively 
(Yusen et al. 2013). Th e half-life of a lung transplant is limited to approximately 5 years (Trulock 
et al. 2007). Fortunately, the overall survival of lung transplant patients has increased steadily 
during  2004 through 2011 (Yusen et al. 2013), and may be even better in single dedicated 
centers.  Verleden et al. has reported up to 75% 5-year survival aft er transplantation in their unit 
(Verleden et al. 2007). However, according to the latest ISHLT report, improvement in survival 
is achieved during the fi rst year aft er transplantation and unfortunately, long-term survival aft er 
the fi rst year has not improved (Yusen et al. 2013). It should be noted that patients who have the 
most urgent need for a transplant due to their critical condition (i.e. pre-operative ventilator, 
and/or extracorporeal membrane oxygenator), have worse out-come aft er operation (Christie et 
al. 2011). 
2.4.  Complica? ons and co-morbidi? es 
Immediate: Primary graft  dysfunction (PGD). PGD is a clinical diagnosis defi ned as severe 
impairment of oxygenation and diff use radiological changes within the fi rst 72 hours aft er 
lung transplantation (Christie, Carby et al. 2005). It is considered to result predominantly 
from ischemia-reperfusion injury (IRI) that was previously used to describe this clinical 
situation. Donor brain death, aspiration episodes, donor infection, cold ischemic preservation, 
and mechanical ventilation all contribute to the development of PGD (Christie, Kotloff  et al. 
2005; Daud et al. 2007). PGD is the leading cause of morbidity and mortality immediately aft er 
transplantation (Christie, Kotloff , et al. 2005, Daud et al. 2007). To diagnose PGD, other immediate 
complications, such as venous anastomotic obstruction, cardiogenic edema, pneumonia and 
hyperacute rejection have to be excluded (Christie, Kotloff , et al. 2005). Hyperacute rejection 
may occur within minutes or hours aft er transplantation, caused by preformed donor-specifi c 
antibodies. 
Early: Infections are the leading cause of death during the fi rst post-operative year (Christie et 
al. 2010). Th e risk for lung transplant infection is always increased, because of direct exposure 
to microbes by inhalation, impaired clearing mechanisms, and immunosuppressive medication. 
Severe infection or recurrent infections may contribute to the development of acute rejection 
(Khalifaf et al. 2004; Kumar et al. 2005). Approximately 10-15% of lung transplant patients 
suff er from diff erent types of airway complications such as stenosis of the bronchial anastomosis 
(Machuzak et al. 2015). 
Acute cellular rejection remains a common complication, especially during the fi rst 6 months 
aft er transplantation (Bando et al. 1995). Acute rejection (AR) develops within days to weeks and 
according to the ISHLT Registry, it occurs at least once in 33% of the patients within the fi rst year 
(Yusen et al. 2013). However, the severity of the manifestation of AR varies signifi cantly. Many 
cases are clinically silent. Development in  antibody detection techniques such as the detection 
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of donor specifi c anti-HLA antibodies (DSA) has revealed that antibody-mediated AR is more 
common than previously thought (Girnita et al. 2004; Cooper et al. 2011). 
Late: Permanent immunosuppressive medication presents risks for lung transplant recipients. 
Th e required immunosuppression is associated with an increased risk for the development of 
renal dysfunction, bone-marrow depression, malignancies, hypertension, metabolic disorder, 
and osteoporosis. Within 5 years aft er transplantation almost 25% of recipients develop 
signifi cant renal dysfunction with a major rise of creatinine levels, or require dialysis or renal 
transplantation. One or more of these renal complications were experienced by circa 40% of 
recipients during the fi rst 10 years aft er the primary operation (Yusen et al. 2013). 
BOS is a major life-limiting factor aft er lung transplantation. It is the leading cause of morbidity, 
lung allograft  loss, and mortality aft er the fi rst post-operative year. Within fi ve years aft er 
transplantation almost 50% of recipients have developed BOS and within 10 years the percentage 
was 76% (Yusen et al. 2013). Patients with BOS have markedly inferior survival at already 5 years 
aft er operation compared to patients with no BOS (Valentine et al. 1996). A median survival 
aft er diagnosis of BOS is reported to be 3 - 4 years (Verleden et al. 2009).
2.5.  Donor organs
According to the Registry of the ISHLT, the number of LTs per year worldwide is approximately 
2100 and is the fasted growing fi eld of solid organ transplantation (Christie et al. 2008). 
However, the number of LTs and its increase are limited due to the shortage of suitable donor 
organs. According to the report of the US Organ Procurement and Transplantation Network 
and the Scientifi c Registry of Transplant Recipients, donor lungs are harvested from only 15% 
of multiorgan donors (Chang and Orens 2006). Due to this, careful patient selection for the 
transplant operation is warranted. Diff erent scoring systems seem to help determining proper 
allocation of the allograft s (Osaki et al. 2009). On the other hand, shortness in the number of 
suitable donor lungs has also led to acceptance of less optimal/marginal donor lungs in some 
centers (Zych et al. 2014) and diff erent strategies have been adopted to increase the amount of 
usable graft s (Valenza et al. 2014). 
Some of the methods of extension of the donor pool are summarized in Table 5. Initial results are 
quite promising, but these methods are not yet widely accepted.
7Table 5. Th e most important methods of extension of the lung donor pool
Donor Comments
1. Donors with extended criteria age > 55 years, smoking history of > 20 pack/year, less than 
optimal gas exchange in otherwise normal lungs (Botha 2006)
2. Donation aft er circulatory death harvesting of organ aft er cardiac arrest (Mason et al. 2008)
3. Lung resection large donor-recipient body size mismatch (Puri and Patterson 
2008)
4. Split lung transplantation the left  lung is split into two separated lobes and implanted to 
the same recipient, the inferior lobe to the left  and superior 
lobe to the right chest cavity (Couetil et al. 1997)
5. Ex vivo lung perfusion Ex vivo perfusion for reconditioning and evaluation of 
marginal donor lungs (Ingemansson et al. 2009, Cypel et al. 
2011)
6. Living lobar harvesting of the right and the left  inferior lobes from two 
diff erent healthy donors (Puri and Patterson 2008)
Young adults (age 18-29 years) comprised 30 % of donors in the recent ISHLT Registry (Yusen 
et al. 2013). Only 1% of the donors were over 65 years old, but the mean age of donors has been 
increasing over the years (Yusen et al. 2013).
However, the major limitation in the number of LTs has been the low amount of recipients in 
Finland. According to the Scandiatransplant registry, the number of patients listed for LT 
in Finland has been the lowest in Scandinavia during the past 10 years, as shown in Figure 1 
(Scandiatransplant Registry 2015, www.scandiatransplant.org). While the lack of referred 
patients may be explained in part by the very low prevalence of cystic fi brosis in Finland, this 
alone does not explain this low number of listed patients in Finland.
Figure 1. Th e number of patients/million people listed for lung transplantation in Scandinavian countries 
during 2005 – 2014. From Scandiatransplant Registry 2015.
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3.  BronchioliƟ s obliterans syndrome
3.1.  Defi ni? on, clinical manifesta? on, and diagnosis
Bronchiolitis Obliterans Syndrome (BOS) is a pulmonary manifestation of chronic lung allograft  
rejection (Estenne et al. 2002). Th e common manifestations of chronic rejection in allograft s 
are chronic infl ammatory and fi broproliterative processes. BOS can be diagnosed on clinical 
grounds during routine surveillance. Th e narrowing of airways causes shortness of breath, which 
is usually the fi rst symptom. As the disease progresses, patients may suff er from continuous 
cough, wheezing and frequent respiratory tract infections (Verleden et al. 2009). 
BOS is defi ned as lung allograft  deterioration secondary to persistent airfl ow obstruction in 
the absence of other conditions that may alter lung allograft  function, such as acute rejection 
and infection. It is characterized by progressive and irreversible decline in forced expiratory 
volume in 1 second (FEV1)  compared to stable post-transplant baseline values. According to 
the ISHLT, the diagnosis of BOS requires a permanent decrease of 20% in FEV1 without other 
explaining factors (Cooper et al. 1993, Estenne et al. 2002). Clinical course in the development of 
BOS is variable. Th e median time from transplantation to the diagnosis of BOS is 16-20 months 
(Verleden et al. 2009). 
One of the major clinical problems is the lack of reliable and repeatable methods to diagnose 
BOS. It is staged into four categories according to severity as shown in Table 6. Although the 
diagnosis of BOS is purely based on lung function measurements, transbronchial biopsies (TBB) 
are recommended for diff erential diagnosis, for example in the evaluation of acute rejection 
(Swanson et al. 2000). Although the specifi city of  TBB is reasonable high, patchy distribution 
of changes in the airway wall makes TBB quite insensitive (Kramer et al. 1993). According to 
previous reports, its sensitivity for BOS may be as low as 31 % for each biopsy specimen, but it 
can be signifi cantly increased by multiplying the amount of tissue specimens (Kramer et al. 1993; 
Reichenspurner et al.1996). Unfortunately, lack of changes in  TBB samples does not exclude 
BOS (Meyer et al. 2014). Bronchoalveolar lavage (BAL), and measurement of exhaled nitric 
oxide fraction can be also used as supportive diagnostic methods (Zheng et al. 2000; Gabbay et 
al. 2000). Chest imaging is an integral part of the evaluation and especially exclusion of other 
processes. Typical radiographic features of BOS are air trapping and bronchiectasis (Ikonen et 
al. 1996; de Jong et al. 2006). However, routine chest radiography is insensitive and non-specifi c 
for diagnosing BOS, but high-resolution computed tomography may detect typical changes more 
accurately (Meyer et al. 2014). 
T able 6. Grading of BOS according to the decrease of forced expiratory volume in 1 second (FEV1) 
(modifi ed from Estenne et al. 2002)
BOS Grade  Classifi cation
0 FEV1> 90% of stable post-transplant baseline value
0-p (probable) FEV1 81-90%
1 FEV1 66–80%
2 FEV1 51-65%
3 FEV1 < 50% 
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3.2  Pathology
Obliterative bronchiolitis (OB; bronchiolitis obliterans) is the histopathological manifestation of 
BOS and  a histologic hallmark of chronic rejection (Stewart et al. 2007). Th e diagnosis of OB, but 
not of BOS, requires histological proof by TBB, open lung biopsy, or autopsy. Pathologically OB 
is restricted to small non-cartilagenous airways or respiratory bronchioles, and characterized by 
submucosal fi brosis of small airways that partially or totally occludes the airway lumen (Stewart 
et al. 2007). Th is scar tissue may be eccentric or concentric, it may be associated with breaks in 
the smooth muscle wall, and may also extend into the peribronchial interstitium (Yousem et 
al.1996). OB is graded as present or absent, irrespective of the presence of infl ammatory activity 
(Stewart et al. 2007).
3.3.  Risk factors
Th ere are several reported risk factors for BOS. Acute rejection (AR) is considered to be the 
most important risk factor (Meyer et al. 2014). However, the data available result mainly from 
retrospective analyses or the ISHLT Registry. In Table 7, suggested risk factors for BOS are listed.
Table 7. Suggested risk factors for BOS (modifi ed from Meyer et al. 2014) 
Risk factor Comments
Acute rejection Multiple and severe ARs increase the risk (Yousem et al. 
1991; Bando et al. 1995)
Lymphocytic bronchitis/bronchiolitis 
(LB)
Precursor of BOS, especially the highest grade of LB 
(Stewart et al. 2007; Glanville et al. 2008)
Primary graft  dysfunction (PGD) Severe PGD increases the risk of BOS (Daud et al. 2007)
Gastroesophageal refl ux (GER) and 
microaspiration
Repeated airway injury may lead to BOS (King et al 2009)
Infection (viral, bacterial, fungal) For example CMV and Pseudomonas aeruginosa may 
increase the risk. Activates immune responses. On the 
other hand, severe infection leads oft en to reduced and 
suboptimal immunosuppressive therapy (Bando et al. 
1995; Reichenspurner et al. 1996; Botha et al. 2008).
Persistent BAL neutrophilia Associated  with the development of BOS (Henke et 
al.1999; Scholma et al. 2000)
Autoimmunity (collagen V 
sensitisation)
Associated  with the development of BOS (Burlingham et 
al. 2007)
Antibody-mediated rejection HLA mismatches and the development of anti-HLA class 
I and II antibodies are associated with BOS (Jaramillo et 
al. 1999; Palmer et al. 2002; Morrell et al. 2009; Safavi et 
al. 2014)
10
Review of the Literature
4.  Pathogenesis of obliteraƟ ve bronchioliƟ s 
4.1.  Lung allogra?  injury 
Several factors contribute to the development of epithelial and endothelial damage during and 
aft er transplantation in the clinical setting, including donor brain death, cold preservation 
and warm ischemia, ischemia-reperfusion injury, surgical techniques, infection, and rejection 
(Carden and Granger 2000,  de Perrot et al. 2003). In the donor, brain death leads to the activation 
of innate immune responses (Rostron et al. 2010). In addition, donors are oft en mechanically 
ventilated before brain death and lungs are exposed to aspiration and infections, which may 
contribute to a proinfl ammatory milieu. During the storage and operation lungs are temporarily 
without blood circulation, before new arterial and venous connections are established. Aft er 
transplantation, ischemia-reperfusion injury and lytic induction therapy induce release a variety 
of pro-infl ammatory factors, including macrophage-derived and epithelial-derived cytokines and 
chemokines (de Perrot et al. 2003). Th ese factors, among others, contribute to an innate immune 
response that leads to bronchial epithelial damage, injury of the subepithelial structures, and 
injury of the vascular vessel endothelium in the allograft . Th is might be one of the key initiating 
events in the development of OB (Yousem et al. 1996). 
Th e allograft  airway blood supply is damaged during the lung transplant operation. Th is probably 
contributes to angiogenic remodelling. Th ere is no clear evidence that lack of revascularisation 
of bronchial arteries would enhance the development of BOS (Langenbach et al. 2005). On the 
other hand, the loss of proper microvasculature most likely contributes to the development of 
OB (Luckraz et al. 2006; Babu et al. 2007; Jiang et al. 2011). However, also angiogenesis and 
neo-vascularisation are detected at the injured airways at the same time (Luckraz et al. 2006). 
Th ese results refer to the complexity of vascular changes in the allograft  and although vascular 
injury and remodelling have been linked to the development of OB, the exact relationship is 
not yet fully defi ned. To prevent or at least alleviate these events, diff erent strategies for organ 
preservation and perfusion have been developed (Keshavjee et al. 1989; Th abut et al. 2001; Cypel 
et al. 2011). Unfortunately, none of these methods are able to prevent tissue damage completely. 
Prolonged allograft  ischemia and ischemia-reperfusion injury may increase the risk of acute 
rejection, and lead to the development of BOS (Fiser et al. 2002). However, in experimental 
heterotopic airway models of OAD, where allograft s suff er from severe ischemia, OAD does not 
develop without alloimmune activation and injury (Koskinen et al. 1997). 
4.1.1. Innate immunity
Innate immunity is the major contributor to acute infl ammation induced by microbial infection 
or tissue injury (Akira et al. 2006). Innate immunity is developed during the evolution of man 
and predominantly does not in itself generate a memory response. It consists of the plasma 
complement system and circulating infl ammatory cells that lead to infl ammatory responses 
via diff erent cascades. Innate immunity is an integral part of the host’s fi rst-line defence against 
invading pathogens (i.e. bacteria, viruses, and fungi), but it is also activated during tissue 
injury of any kind (Land 2007). Many cell types are involved in the process. For example, 
neutrophils, monocytes, natural killer cells, dendritic cells and macrophages mediate the innate 
immune response (Janeway and Medzhitov 2002). On the other hand, both the epithelium and 
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endothelium also contribute to innate immune responses in normal lung (Grossman and Shilling 
2009). It is generally accepted that innate immunity has an integral role in the alloimmune 
response to foreign MHC antigens (Palmer et al. 2003). Although innate immune cells do not 
recognize alloantigens, in the presence of tissue injury or pathogens, innate immune activation 
induces the maturation and migration of antigen presenting cells (APCs, such as dendritic cells) 
to secondary lymphoid tissues, leading to alloantigen-specifi c T and B cell activation. Without 
innate immune activation, alloantigen-specifi c adaptive immune activation is signifi cantly 
decreased (Walker et al. 2006). 
4.1.2. Innate immune cells 
Innate immunity consists of several cell types, each contributing to the infl ammatory response. 
Monocytes are circulating phagocytic cells that are able to internalize and ingest pathogens and 
diff erent particles. A signifi cant part of the bone marrow, splenic, and blood myeloid cells are 
monocytes and they rapidly migrate into sites of infl ammation and give rise to dendritic cells 
or macrophages. It has been shown recently that monocytes migrate into a lung allograft  before 
neutrophils and monocytes actually regulate the transendothelial migration of neutrophils 
(Kreisel et al. 2010). Macrophages produce chemokines and other infl ammatory mediators and 
they are the most effi  cient phagocytes of the innate immune cells and the host`s fi rst-line defense 
against invading pathogens. Both macrophages and DCs also play a key role in the development 
of adaptive immune response as they serve as APC. 
Neutrophils are bonemarrow-derived cells and also capable of phagocytosis and opsonisation of 
internalized bacteria and particles. Th ey are amongst the fi rst-responders to infl ammation and an 
important source of chemokines and other mediators of infl ammation (Morita et al. 2001). Th ey 
also play a role in the development of IRI aft er transplantation (Kreisel et al. 2010). Neutrophils 
migrate to the site of infl ammation/injury within minutes guided by chemotaxis. Neutrophils 
can adhere to the vascular wall with the help of adhesion molecules and transmigrate through 
the endothelium to the site of infl ammation.
Natural killer cells (NK cells) are a subset of lymphocytes which can directly destroy virally-
infected and tumour cells in an alloantigen-independent manner. Th ey express germ-line 
encoded receptors which are able to recognize the loss of self-MHC class I expression in the 
virally-damaged or otherwise transformed cells (missing self theory, Ravetch and Lanier 2000). 
Th ey are the major source of interferon- (IFN- ) production, but they also produce other 
immunosuppressive or proinfl ammatory cytokines and chemokines. As they lack antigen-
specifi c cell surface receptors (Vivier et al. 2011), they have been considered to be a component 
of the innate immunity system. However, recent fi ndings have shown that NK cells also play a 
role in adaptive immune responses and they may be able to create an immunological memory 
(Sun et al. 2009; Vivier et al. 2011).
 
4.1.3. Pa? ern recogni? on receptors
Pattern recognition receptors (PRRs) are germ-line encoded receptors. Th ey recognize and react 
to the ligation of diff erent pathogen-associated molecular patterns (PAMPs) and also endogenous 
host derived damage-associated molecular patterns (DAMPs). During tissue injury, PAMPs and 
DAMPs are formed and released (Aderem and Ulevitch 2000; Janeway and Medzhitov 2002). 
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PAMPs consist of molecules such as bacterial lipopolysaccharides, lipoproteins, peptidoglycan, 
and viral RNA and DNA (Aderem and Ulevitch 2000). On the other side, DAMPs are molecules 
derived from the host`s own damaged cells. Th ese include, i.e., fi brinogen, hyaluronic acid, heat-
shock proteins, and high-mobility group box-1 (HMGB1) (Smiley et al. 2001; Yu et al. 2006). 
Aft er proper ligation, PRRs activate down-stream signaling pathways. Th ere are several distinct 
classes of PRRs in mammals (Akira et al. 2006). Toll-like receptors (TLRs) and complement 
receptors (CRs) are the best characterized subgroups of PPRs.
4.1.4. The Toll-like Receptor System
Toll-like receptors (TLR) play a major role in immunity against diff erent pathogens. Dendritic 
cells (DC), mononuclear phagocytes, polymorphonuclear phagocytes, T lymphocytes, 
endothelial, and epithelial cells are equipped with TLRs (Land 2007). Th ey are detected both 
on the cell surface and in intracellular compartments and at the moment there are 11 identifi ed 
functional human TLRs (Farrar et al. 2013). Together these are able to recognize a basically 
unlimited number of diff erent PAMPs. In addition, TLR2 and -4 also recognize DAMPs (Roach 
et al. 2005; Yu et al. 2006; 2010). Except for TLR3, all other ten TLRs signal through the adaptor 
protein called myeloid diff erentiation factor 88 (MyD88) (Takeda and Akira 2004). Stimulation 
of MyD88 is followed by downstream signaling cascades and production of proinfl ammatory 
cytokines such as tumor necrosis factor (TNF), interleukin-1 (IL-1), IL-6 and chemokines (Akira 
et al. 2006; Janeway and Medzhitov 2002). Stimulation also leads to 
upregulation of antigen presentation by APCs.
4.1.5. The Complement System
Th e complement system is a major player in the generation of the innate response. Th is system 
consists of a large amount of small proteins in the blood. Normally, these proteins are in inactive 
form. Complement is activated through three diff erent pathways (Carroll 2004). Th e classical 
pathway is mainly antibody-mediated, but a wide range of molecules, including DAMPs, can 
activate the alternative pathway and the lectin pathways (Farrar et al. 2013, Wood and Goto 
2012). Activation of any of these pathways leads to the activation of protein C3, which is the 
crucial trigger of the complement cascade (Farrar et al. 2013). Activation of this cascade causes 
chemotaxis and vasodilatation in tissues. At the end of the cascade, three diff erent groups of 
complement eff ector molecules are formed. Th ese eff ector molecules mediate killing (membrane 
attack complex) and phagocytosis (opsonisation) of pathogens. Th ey also serve as ligands for 
complement receptors, which are found on leukocytes and parenchymal cells and this signaling 
mediates and promotes infl ammation (Farrar et al. 2013). Complement activation is markedly 
enhanced in IRI and AR (Pratt et al. 2000; Farrar et al. 2006). In the presence of alloantigens 
complement signaling also enhances antigen uptake and stimulates B- and T-lymphocytes. 
Furthermore, the complement system is an eff ector in the development of antibody-mediated 
immune responses where interaction of the complement and antibody are essential for the 
process (Colvin and Smith 2005). Th is complex signaling system may alter the magnitude 
of the infl ammatory response depending on the prevailing microenvironment. However, 
the understanding of these mechanisms is still limited. Th ere seems to be cross talk between 
complement receptors and TLRs via intracellular signaling (Damman et al. 2011). DAMPs are 
supposed to play a central role in connecting these two systems (Farrar et al. 2013), shown in 
Figure 2.
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Figure 2. Role of the innate immune receptors in the pathway of injury. DAMP; damage-associated 
molecular pattern, TLR; Toll-like receptor, CR; complement receptor. Modifi ed from Farrar et al. 2013.
4.1.6. Innate immune response and adap? ve immunity
Both TLRs and complement receptors are expressed by immature APC. Activation of APCs such 
as DCs and macrophages provides a link between innate and adaptive immune responses (Land 
2007). Although innate immunity responses precede and prepare the ground for the adaptive 
immune responses they are also crucial in the modulation of adaptive immune responses and 
due to this, in the development of rejection. (Palmer et al. 2003; Land 2007). An innate immune 
response is immediate, but its potency is limited, and generally the innate immunity response 
itself cannot reject the allograft  in the absence of adaptive immune activation (Wood and Goto 
2012).  
4.2. Alloan? gens, T cell ac? va? on, and allogra?  recogni? on
Rejection is the major obstacle to successful transplantation. Aft er transplantation, the 
recipient`s immune system considers the donor organ as foreign and tries to remove it from the 
system. Perioperative injury to the lung allograft  initiates innate immune responses that trigger 
the host´s adaptive immune cells to infi ltrate the allograft . Th e presented foreign alloantigens 
are then recognized by the adaptive immune cells of the host eliciting acute allograft  rejection 
(Rogers and Lechler 2001). Th e major histocompatibility complex (MHC) antigens are called 
major alloantigens. Th ere are two diff erent kinds of MHC molecules. Th e MHC class I molecules 
are found on the surface of almost every nucleated cell and they present peptide antigens 
originating from cytosolic proteins. Th e MHC class II molecules are expressed only on the APCs, 
such as dendritic cells, macrophages, B cells and certain activated endothelial and epithelial 
cells. Th e MHC class II molecules present peptide antigens derived from extracellular proteins. 
Human MHC is termed human leukocyte antigen (HLA).
Alloantigens are presented by APCs to recipient’s T cells. In this process, the T cell receptor 
(TCR) complex on the surface of a T cell interacts with the alloantigen which is presented by the 
MHC molecule. Each TCR recognizes a specifi c antigen. TCR engagement with an alloantigen-
MHC complex is the primary requirement for T cell activation (signal 1). A co-stimulatory signal 
is also needed (signal 2). Th ese two signals activate diff erent pathways leading to upregulation 
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and secretion of the T cell growth factor IL-2. IL-2 and other proproliferative cytokines (signal 
3) initia clonal expansion of activated T cells (Whitelegg and Barber 2004). Antigen presentation 
occurs mainly in the allograft  and in secondary lymphoid organs, i.e., lymph nodes and spleen. 
Alloantigen-presentation can take place by three diff erent mechanisms. In direct recognition, 
T cells recognise intact donor MHC molecules expressed by donor APC (Afzali et al. 2008). 
Th e indirect pathway is defi ned by the recognition of processed donor-derived peptides 
presented by recipient APC (Whitelegg and Barber 2004; Afzali et al. 2008). Semi-direct 
recognition occurs, when recipient APC catch intact donor MHC molecules by exchange of 
cell membrane fragments from the donor APC (Afzali et al. 2008). All of these pathways are 
active early aft er transplantation. Th ey are summarized in Figure 3. Th e direct pathway leads to 
a strong alloimmune response rapidly aft er transplantation, and it has been suggested that acute 
allograft  rejection is mainly mediated trough this mechanism. Th e signifi cance of the semi-direct 
allorecognition in rejection is not fully elucidated yet (Wood and Goto 2012). Direct and semi-
direct allorecognition decrease aft erwards, probably due to the decline of donor-derived APCs 
in the allograft . During the later postoperative course, the indirect allorecognition pathway 
is thought to be the most important pathway for late rejection episodes and chronic rejection 
(Illigens et al. 2009). It is also linked to the development of alloantibodies (Rocha et al. 2003). 
Figure 3. Th e direct (A), indirect (B), and semi-direct (C) antigen presentation lead to the 
activation of recipient T cells. DC; dendritic cell, APC; antigen presenting cell. TCR; T cell 
receptor. Modifi ed from Whitelegg and Barber 2004..
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4.3.  Adap? ve immunity, alloimmune response and rejec? on
Aft er activation, T cells start to diff erentiate, and multiple factors contribute to this process. 
Th e status of the microenvironment, the nature of the antigens leading to allorecognition, and 
additional costimulatory signals guide T cell development (Wood and Goto 2012). Th e adaptive 
immune responses may be proinfl ammatory or anti-infl ammatory in nature and this process 
seems to be directed in part by the innate immune activation (Land 2007; Liu and Zhao 2007; 
Wood and Goto 2012). T cells can be divided into CD4+ T cells and CD8+ T cells. Th e CD4+ T 
cells function primarily as helper cells for other immune cells, whereas the CD8+ T cells identify 
foreign MHC class I molecules on target cells and are able to destroy them. Several classes of 
CD4 T cells have been characterized. Each of these subsets is characterized by their own set 
of unique transcription factors and every subset has also distinct cytokine profi les. Th e CD4 
Th 1 cells primarily induce cell-mediated immunity that is characterized by the production of 
proinfl ammatory cytokines such as IFN-, TNF-, via production of transcription factor T-bet 
(Lehmann et al.1997; Stinn et al.1998; Miossec et al. 2009). Th ese cytokines further activate 
monocytes and macrophages leading to the production of cytokines such as IL-2 and IL-12 
(Afzali et al. 2008). Th e CD4 Th 2 cells produce cytokines such as IL-4, IL-5, IL-10, and IL-13 
(Miossec et al. 2009;Rocha et al. 2003), via production of transcription factor GATA 3. Th e 
Th 2 immune response is associated with mucosal, allergic, and humoral immunity. Th e CD4 
Th 3 cells are responsible for mucosal immunity in the gut. IL-9 secreting CD4 Th 9 cells are 
involved in mast cell activation and recruitment and T follicular helper cells are involved in B cell 
maturation in lymph nodes (Wood and Goto 2012). Th e CD4 Th 17 cells mediate the production 
of cytokines such as IL-17 and IL-23, via production of transcription factor RORt (Yuan et al. 
2008). Th 17 response is associated with host pathogen defense, autoimmune reactions and it 
has been also shown to play a central role in allograft  rejection (Yuan et al. 2008; Miossec et 
al. 2009). Th e CD4+ T cells may also become regulatory in nature and thus inhibit and limit 
immune activation in antigen-dependent manner and they may be identifi ed by the expression 
on transcription factor FoxP3 (Long and Wood 2009) and the secretion of cytokines such as 
IL-10 and TGF-. Diff erentation pathways for naïve CD4+ T cells are shown in Figure 3.
Th e activation and diff erentiation of T cells leads to the activation of an eff ector phase, which is 
defi ned by coordinated activity of CD4+ and CD8+ T cells, B cells, mast cells, macrophages, NK 
cells, polymorphonuclear cells, and their regulatory counterparts (Rocha et al. 2003). During the 
process, these cells migrate to the transplanted organ from the secondary lymphoid organ. Th e 
eff ector phase contributes to allograft  rejection and, without proper immunosuppression, actions 
of the eff ector cells fi nally destroy the allograft .
Earlier it was believed that the Th 1 response is mainly responsible for rejection. However, it 
has been recently reported, that Th 2 and Th 17 pathways also have a role in the development of 
rejection, especially of chronic rejection (Yuan et al. 2008; Chadha et al. 2011). It is also reported 
that a Th 1 response might inhibit a Th 2 response and vice versa (Miossec et al. 2009) and both 
responses can suppress the Th 17 pathway (Wynn 2005). Diff erent pathways also overlap and the 
balance can change along with the change of local polarizing conditions (Miossec et al. 2009). 
Recognition of alloantigens leads eventually to the development of life-long antigen-specifi c 
memory T cells (Jones et al. 2006). It has become clear that allograft  rejection is a complicated 
process involving the balance between multiple proinfl ammatory and regulatory pathways and 
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that innate immune activation plays a central role in guiding this process (Land 2007; Wood and 
Goto 2012). 
Figure 4. Diff erentation pathways for naïve CD4 + T cells and hallmark cytokines of each subtype. 
4.4.  Immunomodula? on
Th ere are diff erent populations of T cells that have regulatory activity and are capable of 
preventing transplant rejection. In addition to regulatory T cells, also B cells, macrophages, 
myeloid derived suppressor cells, dendritic cells, and mesenchymal stromal cells are reported 
to have tolerogenic activity (Wood et al. 2012). Th e microenvironmental conditions eventually 
dictate whether these cells contribute to rejection or promote tolerance (Wood et al. 2012). Tregs 
can suppress host immune responses against antigens (Liu and Zhao 2007) and contribute to 
the regulation of rejection. Although TLR-mediated signaling is mainly responsible for innate 
and adaptive immune responses, it may also regulate the function of Tregs (Liu and Zhao 
2007). Th e balance of Tregs and CD4+Th  cells is an important factor that dictates the nature of 
an alloimmune response. If the balance shift s towards tolerogenic  Tregs, the development of 
rejection may decrease. It is not fully understood, which factors contribute to the development 
of a tolerogenic response. One of the common features of regulatory T cells is that these cells 
produce the cytokine IL-10 that favours the development of tolerogenic response (Rubtsov et 
al. 2008). It is also reported that the development of T cells towards Treg phenotypes requires 
the presence of TGF- and a change in the microenvironment is an important factor directing 
immunomodulation (Afzali et al. 2007; Wood et al. 2012).
4.5.  An? body-mediated rejec? on
Antibody-mediated immunity as a signifi cant contributor to lung allograft  rejection has gained 
more interest in the recent years. Naïve B cells are able to recognize diff erent antigens that are 
circulating in the blood or bound to the surfaces of microbes. Although some B cells are able to 
activate independently, the majority of B cells requires the help of T cells (Takemoto et al. 2004; 
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Wood and Goto 2012). However, B cells themselves can sometimes act as APCs and interact 
with T cells due to their expression of MHC class II and co-stimulatory molecules (Tarlinton 
et al. 2008). Recognition leads to clonal expansion and diff erentiation of B cells and during 
this process, B cells mature to antibody secreting plasma cells (Colvin and Smith 2005). Th ese 
antibodies are specifi c for the recognized alloantigen and they are the eff ector molecules of the 
humoral immunity. Th ey are able to neutralize antigens and mark them for the phagocytes. B 
cells also express complement receptors and they are able to recognize complement-coated cells 
(Carroll 2004).  Aft er the eff ector phase, some of the plasma cells transform to memory cells, 
capable of a quick response to the same antigen. If the immune system is to be exposed to the 
same antigen, again these cells contribute to the development of a rapid and strong alloimmune 
response. Th is immunological memory is highly benefi cial against invading pathogens. However, 
in transplantations, immunological memory is harmful and may lead to acute rejection and PGD. 
If the recipient has preformed alloantibodies before the transplant operation, these antibodies 
may cause hyperacute antibody-mediated rejection (Glanville 2010).
4.6.  Rejec? on and development of OB
An allograft  suff ers diff erent injuries aft er transplantation. Th e number and severity of these 
injuries contribute to alloimmune activation and rejection episodes via innate immunity 
(McDyer 2007).  Genetic factors of the recipient may also have an important role in determining 
the quality and magnitude of the immune responses (Lu et al. 2002) and the patient may be 
sensitized to the donor alloantigens prior to transplantation, further promoting a robust 
alloimmune activation. Together, all these factors contribute to the development of rejection 
episodes. While the current immunosuppression suppresses adaptive T and B cell responses, its 
use is accompanied by side eff ects and toxicity related to the immunosuppression. Furthermore, 
infections and other causes of graft  injury such as aspiration may induce innate immune 
activation and thereby adaptive immune responses leading to allograft  rejection and injury via 
either cell-mediated or antibody-mediated mechanisms. Th e rejection response may be clinically 
evident and as stated before, acute rejection is the leading risk factor for BOS (Yousem et al. 
1991; Bando et al. 1995). However, many patients develop BOS without evidence of clinical acute 
rejection. It is likely that these patients had clinically silent smouldering alloimmune activation 
and allograft  injury.  
In the long run, repeated bronchial epithelial damage and injury of the subepithelial structures 
lead to activation and proliferation of fi broblasts and myofi broblasts. Th is leads to excessive 
fi broproliferation, due to ineff ective epithelial regeneration and aberrant tissue repair (Yousem 
et al. 1996). Non-alloimmune mechanisms activate the innate immune response and thereby 
the adaptive immune response. Th is is why syngenic graft s do not develop BOS even if they 
suff er from aspiration, for example. Only mild obliterative changes are observed in experimental 
models of OB when the allograft  lumen is lined with epithelium supporting the notion that 
continuous epithelial injury is central for the development of OB (King et al. 1997, Koskinen et 
al. 1997). 
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5.  Immunosuppression aŌ er lung transplantaƟ on
Immunosuppression aft er lung transplantation remains a diffi  cult issue. Optimal treatment 
should maintain a balance between infection and rejection. To prevent both acute and chronic 
allograft  rejection, multi-drug therapy must be used to achieve control of multiple immune 
pathways. Th e current clinically used immunosuppressive medication primarily targets host T 
cell activation in diff erent ways. 
Th e so called “triple drug” immunosuppression is the cornerstone of anti-rejection therapy. It 
consists of a calcineurin inhibitor (cyclosporine or tacrolimus), an antimetabolite (azathioprine 
or mycophenolate mofetil/ mycophenolic acid), and corticosteroids (Korom et al. 2009). 
Calcineurin inhibitors inhibit the calcineurin pathway and prevent transcription of IL-2 genes 
involved in T cell activation. Antimetabolic agents have an eff ect on nucleotide metabolism and 
inhibit T and B cell proliferation. At the moment multiple combinations of diff erent medications 
are possible. According to the ISHLT Registry, the combination of tacrolimus and mycophenolate 
mofetil (+ corticosteroid) is the most common immunosuppressive therapy for lung transplant 
patients (Christie et al. 2012). Other widely used combinations are tacrolimus and azathioprine, 
and cyclosporine (CsA) and mycophenolate mofetil (Christie et al. 2012). Mammalian target 
of rapamycin inhibitors, like sirolimus and everolimus, may be used to replace the calcineurin 
inhibitor or antimetabolite in some patients (Korom et al. 2009). In addition, at the time of 
transplantation, many centers use so-called induction agents, e.g., monoclonal antibodies (e.g. 
daclizumab, a blocker of the -subunit of the interleukin-2 receptor) or antithymocyte globulin 
to deplete the recipient immune system in the immediate post-transplant period to prevent acute 
rejection (Ailawadi et al. 2008). Th e use of any type of induction therapy has increased in recent 
years, but there is no established protocol for the use or choice of these therapies (Christie et al. 
2010). According to the ISHLT report, the amount of patients with acute rejection was highest 
with CsA-based regimens and lowest with tacrolimus-based regimens during the years 2004-
2009 (Christie et al. 2010).
6.  Treatment of BOS
Surgical techniques and immunosuppressive therapies in the treatment of lung transplant 
recipients have greatly developed since the early 1980s. However, no treatment for BOS is 
available. Present immunosuppressive medication is targeted mainly to the suppression of 
adaptive immune responses, but this does not suffi  ce, as most lung transplant recipients 
experience late allograft  dysfunction of some degree in the form of BOS (Belperio et al. 2003; 
Yusen et al. 2013). When BOS is fully developed, there is no effi  cient way to stop or reverse the 
process. Th e main therapy for clinical BOS is augmentation of immunosuppression or changing 
immunosuppressive medications within therapeutic classes, for example, converting CsA to 
tacrolimus (Meyer et al. 2014). More intensive immunosuppression, such as steroid boluses have 
also been used, but long-term high-dose corticosteroid treatment should be avoided because of 
its severe side eff ects and increased risk of infection (Meyer et al. 2014). All these treatments 
may stabilize lung function or delay the progression for a while in some patients, but the benefi ts 
and effi  cacy of these therapeutic modalities are inconsistent. Th ere is also no clear evidence 
supporting one drug or a drug combination over another (Belperio et al. 2003; Meyer et al. 
2014). Furthermore, intensifi ed immunosuppression may not have any clear eff ect on BOS, if 
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there are no signs of ACR, antibody-mediated rejection, or neutrophilia in BAL samples (Meyer 
et al. 2014). 
Th erapies modulating immune response, such as extracorporeal photopheresis, and total 
lymphoid irradiation have been used with varying results in some lung transplant recipients 
with BOS, but the benefi cial eff ects are based on retrospective cohorts and case-reports, and no 
prospective randomized data exists to support the use of these modalities (Slovis et al. 1995; 
Diamond et al. 1998). Anti-refl ux surgery could be benefi cial for the patients with proven 
gastroesophageal refl ux (GER) at the onset of BOS, but again the results are contradictory at best 
(Cantu et al. 2004; Burton et al. 2009). Patients with neutrophilic reversible allograft  dysfunction 
have neutrophilia in the airways, which may respond to azithromycin therapy (Verleden et al. 
2013).
As a last option, lung retransplantation should be considered for patients with severe BOS. 
Nowadays the survival aft er retransplantation is comparable to fi rst-time transplant patients 
in experienced centers, and evaluation for retransplantation is recommended for end-stage 
BOS recipients in the latest ISHLT guideline (Meyer et al. 2014). However, retransplantation is 
not appropriate for the majority of these patients and the evaluation process should be highly 
selective (Meyer et al. 2014). 
7.  Novel and experimental methods in the treatment of BOS
At the moment, it seems that the best way to deal with BOS is to try to prevent its development. 
During the transplantation procedure, injury to the lung transplant during brain death, 
procurement, surgery and IRI should be minimized. Th is might decrease the innate immune 
response and altogether these actions could also have an impact on the development of the 
adaptive immune response, rejection, and the development of BOS. Th erefore, prevention 
of initial allograft  injury may be one of the most important factors in the treatment of lung 
transplant patients and novel therapeutic options are needed.
7.1.  HMG-CoA reductase inhibitors (sta? ns) 
Statins are a group of drugs that inhibit the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase and eff ectively lower blood cholesterol. Statins inhibit the conversion of 
HMG-CoA to L-mevalonic acid, thereby preventing the synthesis of important isoprenylated 
proteins, which control diverse cellular functions. Th e so-called pleiotropic eff ects of statins are 
lipid-independent and have important vasculoprotective and immunomodulatory properties 
(Bonetti et al. 2003; Wang et al. 2008). Statins improve vascular endothelial cell function (Koh 
2000; Endres et al. 1998; Tuuminen et al. 2011; 2013). Especially, statins are reported to have 
lots of highly varied anti-infl ammatory eff ects, i.e., inhibition of cell adherence and movement, 
T cell proliferation, and alteration of cytokine production (Johnson et al. 2003). Th e inhibition 
of infl ammation may be partially explained by HMG-CoA independent lymphocyte function-
associated antigen (LFA)-1 inhibition on T cells (Weitz-Schmidt et al. 2001). Th is may lead to 
reduced adhesion and activation of lymphocytes (Weitz-Schmidt et al. 2001).
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Endothelial dysfunction is characterized by impaired synthesis, and release and activity 
of endothelial-derived nitric oxide (NO). It has an impact on vascular relaxation and the 
reduction of NO production leads to vasoconstriction. NO also inhibits platelet aggregation 
and vascular smooth muscle cell proliferation and plays a role in the interaction of 
endothelium and leukocytes (Harrison 1997, Laufs and Liao 2000). Statin treatment is 
known to increase NO bioavailability through stabilization of endothelial NO synthase 
(eNOS) mRNA (Laufs et al. 2000). Both eNOS and inducible NOS (iNOS) are produced 
by pulmonary epithelial cells and may have both pro- and anti-infl ammatory properties. 
Increased NO expression was reported during infection and BOS in endobronchial biopsies 
and exhaled air aft er lung transplantation (Gabbay et al. 2000). High levels of exhaled NO 
are also seen during eosinophilic airway infl ammation, such as exacerbation of asthma (de 
Jongste et al. 2005). In contrast, NO stimulates the activity of thioredoxin, a known scavenger 
of reactive oxygen species (Haendeler et al. 2002). We have previously demonstrated that 
blocking NO production with aminoguanidine accelerates while supplementation of the NO 
pathway with L-arginine slows the development of OAD and decreases the rate of epithelial 
loss (Kallio et al. 1997). 
Accumulating experimental evidence supports a benefi cial role for statins also in the 
improvement of airway epithelial cell function during infl ammation, and diff erent pulmonary 
diseases (Johnson et al. 2003; Murata et al. 2005, Ahmad et al. 2011, Liu et al. 2014) but there 
is only little data on statins in lung transplantation and the development of BOS at the moment 
(Johnson et al. 2003; Li et al. 2006). 
7.2.  Hypoxia-inducible factor
Severe infl ammation usually causes hypoxia in the target tissue. Metabolic demands of 
the cells increase during infl ammation, and on the other hand, a reduction of metabolic 
substrates (oxygen for example) occurs at the same time (Eltzschig and Carmeliet 2011). 
During this event both the innate immune response and hypoxic response are activated 
(Rius et al. 2008).  Th e cellular response to hypoxia is regulated by transcription factors 
called hypoxia-inducible factors (HIF) (Semenza et al. 1991; Semenza 2000). HIFs are the 
principle regulators of hypoxic adaptation, regulating gene expression involved in glycolysis, 
erythropoiesis, angiogenesis, proliferation, and stem cell function under hypoxia (Imtiyaz 
and Simon 2010). On the other hand, nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-B) is an essential mediator for infl ammatory responses and the NF-B pathway 
primes the HIF-1 pathway through transcriptional regulation of HIF-1 (Rius et al. 2008). 
Th is interplay increases HIF-1 mediated adaptive functions especially during hypoxic 
infl ammation (Bruning et al. 2012).
HIF-1 is a master regulator of cellular hypoxic adaptation (Semenza 2000). It is a heterodimer 
transcription factor constituting of HIF-1 and HIF-1ß subunits that is known to regulate 
the expression of multiple genes (Imtiyaz and Simon 2010). Both HIF subunits are produced 
at a constant rate and while HIF-1ß is stable, HIF-1 is extremely fragile at normal oxygen 
concentrations and is rapidly degraded via an ubiquitin-mediated pathway (Salceda and 
Caro 1997). HIF-1 has an essential role in infl ammatory responses of myeloid cells (Cramer 
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et al. 2003; Doedens et al. 2010). Leukocytes of myeloid origin – including neutrophils, 
monocytes/macrophages and dendritic cells - are essential for both innate and adaptive 
immune responses. Cramer et al. have shown that HIF-1 is an important in the regulation 
of myeloid cell aggregation, invasion and motility (Cramer et al. 2003). Furthermore, the 
overexpression of HIF-1  in macrophages leads to enhanced phagocytosis (Anand et al. 
2007). HIFs also support the innate immune functions of dendritic cells, mast cells and 
epithelial cells (Nizet and Johnson 2009). On the other hand, HIF-1 acts as an adaptive and 
survival factor for ischemic tissue (Semenza 2000; Prabhakar and Semenza 2012).
Th e Von Hippel Lindau protein (pVHL) is crucial for the execution of HIF proteolysis. 
Absence or genetic inactivation of VHL leads to stabilization of both HIF isoforms, HIF-1 
and HIF-2 even under normoxic conditions (Jaakkola et al. 2001; Krieg et al. 2000). Th ese 
both have diff erent cell type-specifi c functions, which however, may partially overlap. For 
example, macrophages and neutrophils are able to express both HIF-1 and HIF-2, but 
HIF-2regulates mainly the key neutrophil functions (Poitz et al. 2014; Th ompson 2014). 
pVHL has also functions not involving HIFs, as it can regulate intracellular junctions and 
also NF-B signaling among other things (Calzada et al. 2006; Yang et al. 2007). However, 
most of the pathological alterations detected in VHL knock-out mice are developed due to 
constant activation of HIF signaling (Kapitsinou and Haase 2008). 
Th e role of HIFs and VHL in solid organ transplantation is not fully understood, yet. 
Perioperative ischemia contributes to graft  dysfunction and ischemia promotes sustained 
HIF-1 expression. HIF-1 plays an important role in the regulation of myeloid cell 
aggregation, invasion, and motility (Cramer et al. 2003). On the other hand, HIF-1 acts as 
an adaptive and survival factor for ischemic tissue (Semenza 2000; Prabhakar and Semenza 
2012). Th erefore, the fi nal eff ect of HIF-1 might be dualistic and in any case, multifactorial. 
8.   Mouse and rat tracheal transplantaƟ on as a model for OB
Th ere are several experimental animal models to investigate the development of acute and 
chronic rejection aft er lung transplantation (Hele et al. 2001; Sato et al. 2009). Th ese are listed in 
Table 8.
Table 8.  Experimental models of OB (Hele et al. 2001; Sato et al. 2009)
Model Description
Orthotopic lung transplantation Murine models: a single lung is transplanted to 
anatomical position in the recipient
Orthotopic tracheal transplantation Murine models: trachea is transplanted to anatomical 
position in the recipient
Intrapulmonary tracheal transplantation Murine and pig models: tracheal is transplanted inside 
the lung tissue
Heterotopic tracheal transplantation Murine models: trachea is transplanted into the 
omentum (rat) or into a subcutaneus pouch (mouse)
Large animal lung transplantation e.g. pigs; mimics human transplant operation
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Hertz and colleagues were the fi rst to describe the murine heterotopic tracheal transplant model 
in 1993 (Hertz et al. 1993). In this model, the donor trachea is inserted into a subcutaneous 
pouch in the recipient and the model is highly reproducible (Hertz et al. 1993). Later, this model 
was introduced to the rat (Huang et al. 1995). Th e diff erence between these two models is that in 
rats the tracheal graft  is wrapped in to the greater omentum during laparotomy. Using mouse and 
rat tracheal allograft s, it is possible to achieve accelerated development of OAD, histologically 
mimicking human OB (Hele et al. 2001; McDyer 2007; Sato et al. 2009).
Several factors contribute to the development of epithelial and endothelial damage during and 
aft er transplantation in the clinical situation (Carden and Granger 2000,  de Perrot et al. 2003). 
Instead, in a non-vascularised rat and mouse tracheal transplantation model, revascularisation 
of the trachea is slower and this limits the immediate evaluation of reperfusion injury, but 
prolonged ischemia causes severe injury to the epithelium. In these models, there is an ischemic 
phase in the tracheal graft  for the fi rst 2 - 3 days aft er transplantation, before the tracheal neo-
vascularisation develops (Hele et al. 2001, McDyer 2007). Due to prolonged ischemia, the 
respiratory epithelium undergoes ischemic damage in both syngeneic and allogeneic graft s (Hele 
et al. 2001). In syngraft s, the epithelium recovers, the lumen remains completely open, and the 
trachea is lined with normal epithelium in 30 days aft er transplantation. In allograft s in non-
immunosuppressed recipients, the epithelium sustains progressive damage leading to total loss of 
epithelium. Allograft s develop a strong alloimmune response, that peaks at 10 days, culminating 
in the occlusion of the tracheal lumen at 30 days (Hele et al. 2001).
We chose to use the murine heterotopic tracheal allograft  model in all experiments of this 
study, because our group has 20 years of experience with this model (the fi rst study published 
by Koskinen et al. in 1997). Furthermore, the transplantation operation is rather simple, the 
learning curve is short, and almost all the operations are uneventful. Due to these reasons, the 
model is reproducible and the expenses are bearable.
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AIMS OF THE STUDY
We hypothesized that innate immune activation plays a central role in the development of OB. 
We investigated whether inhibition of innate immune activation through diff erent pathways 
could infl uence the development of experimental OB. To test our hypothesis, we investigated 
diff erent factors and pathways leading to obliterative airway disease (OAD) using both rat and 
mouse tracheal allograft  models. A special emphasis was placed on the heterotopic tracheal 
allograft  model itself, the innate immune response, the role of simvastatin treatment, and the role 
of HIF-1 and VHL expression in the innate immune cells in the development of OAD.
Th e specifi c aims of the study were:
Study I: to characterize the innate and adaptive immune responses in OAD.
Study II: to dissect the role of simvastatin treatment in the development of OAD.
Study III: to investigate the eff ect of myelomonocytic cell-targeted deletions of HIF-1a or its 
negative regulator VHL on the development of OAD.
Aims of the Study
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Methods
METHODS
1.  Heterotopic rat tracheal transplantaƟ ons
Specifi c pathogen-free inbred male Dark Agouti (DA; AG-B4, RT1a) and Wistar Furth (WF; 
AG-B2, RT1u) rats weighing 200-300 g and of 2-3 months of age (Scanbury, Sollentuna, 
Sweden) were used. Th e rats received care in compliance with the “Guide for the Care and 
Use of Laboratory Animals” prepared by the National Academy of Sciences and published 
by the National Academy Press (ISBN 0-309-15400-6, revised 2011). Permission for animal 
experimentation was obtained from the Provincial State Offi  ce of Southern Finland. 
A 3-cm long segment of the donor trachea was excised just above the bifurcation, perfused 
with PBS containing 10 000 IU/ml penicillin and 1000 μg/ml streptomycin, and stored in the 
same solution at +4°C until transplantation. In the recipient, the trachea was wrapped into 
the greater omentum and the abdomen was closed using absorbable continuous 3-0 sutures. 
Isofl urane (Isofl uran, Baxter, Deerfi eld, IL) and buprenorphine (Temgesic, Schering-Plough, 
Kenilworth, NJ) were used for anesthesia and perioperative analgesia and buprenorphine 
was also used for postoperative pain relief.
Syngeneic tracheal graft s were transplanted  from DA donors to DA recipients and fully-
MHC mismatched allograft s from DA donors to WF recipients into the recipient greater 
omentum, and the graft s were removed at 3, 10 and 30 days aft er transplantation. Non-
transplanted DA tracheas were used as normal controls. 
2.  Heterotopic mouse tracheal transplantaƟ ons
Allogeneic tracheal transplantations were performed from specifi c pathogen-free fully MHC-
mismatched Balb/C (Scanbur, Sollentuna, Sweden) donors to mixed Sv129/C57B1/6/CB.20 
recipients with HIF-1 or VHL gene deletion in the myeloid-cell lineage. Gene deletion 
confi ned to neutrophils and macrophages was achieved by mating the  Sv129/C57B1/6/CB.20 
mice containing loxP sequences on either side of the target gene (HIF-1 or VHL) with Sv129/
C57B1/6/CB.20 mice carrying the LysMCre recombinase (Clausen et al. 1999). Th e result is mice 
that are defi cient in either HIF-1 or VHL alleles in all myeloid cells (later defi ned as mHIF-
1alpha-/- or mVHL-/-). Th is was controlled by genotyping the animals used in the experiments. 
Littermates (LM) served as negative controls. All mice were male, weighed 25-30 g and were 2-3 
months of age. 
A 1.5-cm long segment of the donor trachea was excised just above the bifurcation, perfused with 
PBS containing 10 000 IU/ml penicillin and 1000 mcg/ml streptomycin, and stored in the same 
solution at +4°C until transplantation. In the recipient, the trachea was set into the abdominal 
subcutaneous pouch and the wound was closed using absorbable continuous 6-0 sutures. 
Tracheal allograft s were heterotopically transplanted from Balb/C donors to MHC-mismatched 
recipients with HIF-1alpha (mHIF-1-/-) or VHL (mVHL-/-) defi ciency in myelomonocytic cells. 
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3.  Drug regimens
3.1.  Rat-experiments (studies I and II):
Cyclosporine A (study I): CsA (Novartis, Basle, Switzerland) was dissolved in Intralipid 
(KabiVitrum, Stockholm, Sweden) to a fi nal concentration of 1 mg/ml. CsA was administered 
daily at a dose of 0, 1.0 or 1.5 mg/kg s.c. from the operation day until sacrifi ce. Th e doses 
were based on our previous dose-response study with this animal model (Koskinen et al. 
1997). 
Simvastatin (study II): Simvastatin (kindly supplied to us by MSD Finland, Helsinki, Finland) 
is a lipophilic member of the statin group. Simvastatin diluted in polyethylene glycol (PEG, 
molecular weight 300, Sigma-Aldrich, Steinhein, Germany) was administered at doses of 0.1, 
0.5, 2, 5, to 20 mg/kg daily via nasogastric tube, throughout the study. Polyethylene glycol (PEG) 
was used as vehicle in control animals. In the simvastatin study, no immunosuppression was 
administered to avoid drug interactions.
L-NAME (study II):  In order to clarify whether simvastatin mediates its eff ects via NO-activity, 
N(omega)-nitro-L-arginine methyl ester (L-NAME) was used to inhibit nitric oxide synthase 
(NOS) action. L-NAME was administered in drinking water aft er transplantation at a 
concentration of 1g/L. 
3.2.  Mouse-experiments (study III):
Tacrolimus: Animals received tacrolimus 0.75 mg/kg daily subcutaneously. According to our 
previous studies with this animal model this dose leads to partial occlusion of the tracheal 
allograft s (Hollmen et al. 2008). Again, the idea was to try to delay the development of OAD 
rather than to prevent it totally. By this method, we were able to investigate if the role of HIF-1 
in myelomonocytic cell is protective or deleterious  in the development of OAD and if potential 
benefi cial eff ects are still detected with mild immunosuppression.
4.  Histological evaluaƟ on
For histological evaluation, sections were stained with Mayer`s hematoxylin and eosin 
(H&E). Histological changes in the respiratory epithelium were evaluated as the percentage of 
circumference not covered by epithelium. Luminal occlusion was evaluated as the reduction in 
luminal area using NIH Image program version 1.59 (U.S. National Institutes of Health, National 
Technical Information Service, Springfi eld, VA). All analyses were done in blinded review by two 
independent observers. 
5.  Immunohistochemistry
Immunohistochemistry was performed using the Vectastain Elite ABC Kit (Vector Laboratories, 
Burlingame, United States) on serial frozen sections (4-6 μm). Th e specimens were counterstained 
with hematoxylin and cover slips were aquamounted (Aquamount; BDH Ltd., Poole, UK). Th e 
reaction was revealed by 3-amino-9-ethylcarbazole (AEC; Vector Laboratories). Th e number 
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of cells was recorded by counting positive staining cells/cross section using a grid and x400 
magnifi cation and moving the grid across the tracheal cross section in two perpendicular lines. 
Th e negative controls showed no immunoreactivity. Antibodies and dilutions used are shown in 
Table 9 (studies I-II) and Table 10 (study III). All analyses were performed in a blinded manner 
by two independent observers. 
Table 9. Antibodies used in the studies I and II
Antibody Catalogue number Dilution Source
CD4+ T cells 554835 5 μg/ml BD Pharmingen
CD8+ T cells 554854 5 μg/ml BD Pharmingen
ED1+ macrophages 22451D 5 μg/ml BD Pharmingen
ICAM adhesion molecule ab33894 10 μg /ml Abcam
Ki-67+ proliferative cells NCL-Ki67p 8-12 mg/ml Novocastra Laboratories Ltd
MHC class II MCA46R 10 μg /ml Serotec
MPO+ neutrophils ab9535 20 μg/ml Abcam
OX-62+ dendritic cells MCA 1029G 10 μg/ml Serotec
RECA-1 MCA970 50 μg /ml Serotec
VCAM adhesion molecule MMS-141P 1 μg/ml Covance
Table 10. Antibodies and dilutions used in the study III
Antibody Catalogue number Dilution Source
MPO+ neutrophils ab9535 20 μg/ml Abcam
CD11b+ macrophages 557394   5 μg/ml BD Biosciences
CD4+ T cells 553043   5 μg/ml BD Biosciences
CD8+ T cells 553027   5 μg/ml BD Biosciences
CD11c+ dendritic cells ab33483 10 μg/ml Abcam
6.  RNA isolaƟ on and quanƟ taƟ ve real-Ɵ me PCR
Total RNA was isolated from tissue samples dissected from tracheas using RNeasy kit 
(Qiagen, Hilden, Germany) and reverse transcribed with High-RNA-to-cDNA kit (Applied 
Biosystems, Foster City, CA). Quantitative real-time RT-PCR (qRT-PCR) was performed 
on a RotorGene-6000 (Corbett Research, Doncaster, Australia) using 2X DyNAmo Flash 
SYBR Green Master mix (Finnzymes, Espoo, Finland). The amount of mRNA used for 
reverse transcription was approximately 100 nanograms. Measurement of the PCR product 
was performed at the end of each extension period. Th e mRNA quantities of the factors 
seen in Table 11 were measured from each group. Stability of the housekeeping genes 
18sRNA, ß-actin, GAPDH, and TBP was determined using geNorm application version 3.2 
(PrimerDesign, Southampton, UK), and the most stable gene was chosen for normalization. 
Data was normalized against GAPDH (study I, phase 1 and study II), TBP (study I, phase 2), 
or 18sRNA (study III). Th e number of mRNA copies of the gene of interest was calculated 
from a corresponding standard curve using RotorGene (Corbet Research) soft ware. 
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Table 11. Th e mRNA quantities of the factors shown in the table were measured from each group 
Molecule
innate immune ligands hyaluronic acid synthase (HAS) 1, 2, 3
TLR 2, 4 
HMGB1, NF-kb
infl ammatory cytokines TNF-α, IL-1β, LFA1, CINC-1, MCP-1, CCL20
dendritic cell maturation markers CD86, CD83
secondary lymphoid chemokine and its receptor CCL21, CCR7
Th 1-related transcription factor and cytokines T-bet, IFN-g, IL-12 (subunit p35), IL-2, IP-10
Th 2-related transcription factor and cytokines GATA-3, IL-4
Th 17-related transcription factor and cytokines RORc, IL-6, IL-23, IL-17A, IL-17F, IL-17E
T-regulatory transcription factor and cytokines Foxp3, IL-10
lymphocyte adhesion molecules LFA-1
T cell diff erentiation factors KLF2
costimulatory signaling CD40, CD40L
endothelial peptides ET-1
heme oxygenase enzymes HO-1
growth factors transforming growth factor (TGF)- ß
platelet derived growth factor (PGDF) –a
connective tissue growth factor (CTGF)
7.  StaƟ sƟ cal Methods 
All data are expressed as mean ± SEM. An appropriate parametric or non-parametric test was 
used for statistical evaluation, depending on the situation. Parametric Student`s T test was used 
for two group comparisons. ANOVA-test with Dunnett`s correction was used for parametric 
multiple group comparison. Analyses were made using SPSS for Windows version 15.0 
(SPSS Inc., Somers, NY, IL). Non-parametric Mann-Whitney U-test was used for two group 
comparisons (study III). P ≤ 0.05 was regarded as statistically signifi cant.
Methods
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Results
RESULTS
1.  The development of obliteraƟ ve airway disease in rat tracheal 
allograŌ s (studies I and II)
First, we decided to validate the heterotopic allograft  model for the aims of this study. We 
compared the histological changes of respiratory epithelium and the degree of luminal occlusion 
of tracheal syngraft s and allograft s at 3, 10, and 30 days aft er transplantation. During the ischemic 
phase at 3 days, both syn- and allograft s showed a marked loss of epithelium, and no signifi cant 
diff erence was seen in the extent of epithelial loss between syn- and allograft s (Fig. 1A, B, E). In 
syngraft s, epithelium rapidly recovered and trachea was already lined with epithelium at 10 days 
(Fig. 1A, C). At 30 days, the respiratory epithelium of syngraft s was fully recovered, and the graft s 
were fi lled with mucus, a sign of normal epithelial function (Fig. 1A, D). In allograft s, there was 
an almost total loss of epithelium already at 10 days and no epithelial lining was detected in any 
of the allograft s at 30 days (Fig. 1A, F, G). 
Figure 1. Th e development of epithelial injury in rat tracheal allograft s. Heterotopic rat tracheal 
transplantation model. For histological evaluation, the tracheal sections were stained with Mayer`s 
hematoxylin and eosin (H&E). Th e histological changes in respiratory epithelium were evaluated as the 
percentage of circumference not covered by epithelium (A).  Illustrative photomicrographs of tracheal 
epithelium (B-G) of the syngraft s and the allograft s at day 3, 10, and 30.Original magnifi cation x80. 
Data is expressed as mean ± SEM. n=6 per group. *P<0.05, **P<0.01,***P<0.001. E, epithelium; L, 
lumen. Modifi ed from study I.
In syngraft s, no tracheal occlusion occurred, and the overall histology resembled that of non-
transplanted tracheas (Fig. 2A-D). In allograft s, the luminal area was reduced by a progressive 
fi broproliferative lesion that almost totally occluded the lumen at 30 days (Fig. 2A, E-G).
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Figure 2. Th e development of OAD in rat tracheal allograft s. Heterotopic rat tracheal transplantation 
model. For histological evaluation, the tracheal sections were stained with Mayer`s hematoxylin and 
eosin (H&E). Luminal occlusion was evaluated as the reduction in luminal area (A). Illustrative 
photomicrographs of tracheal cross-sections (B-G) of syngraft s and allograft s at day 3, 10, and 30. 
Original magnifi cation x40. Data is expressed as mean ± SEM. n=6 per group. *P<0.05, **P<0.01, E, 
epithelium. Modifi ed from study I.
2.  AlloanƟ gen dependent Th1 and Th17 responses emerged 
during the development of obliteraƟ ve airway disease in non-
immunosuppressed recipients (study I)
Aft er the validation, we focused on the mechanisms of the development of OAD in this model. 
Allograft s were compared to syngraft s, while syngraft s were compared to normal tracheas. As 
syngraft s have no foreign MHC antigens when compared to allograft s, they may be used for 
the evaluation of the magnitude and mechanisms of innate immune response caused by 
ischemia and the operation itself without a superimposed alloimmune response as seen in the 
allograft s. In syngraft s, signifi cantly increased infi ltration of ED1+ macrophages and CD8+ T 
cells was observed at 3 and 10 days and of CD4+ T cells at 10 days, when compared to normal 
nontransplanted tracheas. Innate immune activation was observed during the ischemic period in 
both syn- and allograft s at 3 days. In the allograft s, a more prominent infi ltration of these cells 
and OX62+ dendritic cells was observed especially at 10 days (Fig. 3A-J). 
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Figure 3. Th e increased infl ux of infl ammatory cells aft er ischemia was strongly alloimmune related. 
Here is shown the number (x100) of MPO+ neutrophils, ED-1+ macrophages, CD4+ T cells, CD8+ T cells, 
and OX-62+ DCs in cross-sections of normal tracheas and of syngraft s and allograft s at day 3 (A-E) and 
at day 10 (F-J). Data is expressed as mean ± SEM. n=6 per group. *P<0.05. Modifi ed from study I.
In syngraft s, the mRNA expression of proinfl ammatory, but also of tolerogenic cytokines 
was signifi cantly upregulated (Fig. 4A, D, E, H), whereas Th 1 and Th 17 priming factors were 
downregulated (Fig. 4C, F, G). In allograft s, prominent mRNA expression of proinfl ammatory 
cytokines was seen (Fig. 4A). Adaptive Th 17 alloresponse was increased aft er the ischemic period 
at 3 days (Fig. 4C). Adaptive immune response modulated the expression of cytokines mainly 
towards Th 1 at day 10 (Fig. 4F). However, the expression of tolerogenic Treg transcription factor 
FoxP3 was also signifi cantly increased at that point (Fig. 4H).
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Figure 4. Adaptive immune response modulates the expression of cytokines mainly towards Th 1 during 
the development of OAD in non-immunosuppressed recipients. qRT-PCR analysis was performed  and 
mRNA levels of innate and adaptive immunity cytokines and receptors were measured from normal 
tracheas and from syngraft s and allograft s at day 3 (A-D) and 10 (E-H). Data is expressed as mean ± 
SEM. n=6 per group. mRNA data normalized against 18S rRNA. *P<0.05. Modifi ed from study I.
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3.  Cyclosporine A treatment reduced Th1, Th2, and Th17 
responses and decreased the development of obliteraƟ ve 
airway disease in tracheal allograŌ s (study I) 
In the second phase of the study, we wanted to evaluate the eff ects of CsA treatment in 
tracheal allograft s. CsA treatment prevented the loss of epithelium and the development of 
OAD in a dose-dependent fashion (Fig. 5A-B). Furthermore, CsA suppressed Th 1, Th 2, and 
Th 17 responses but also inhibited the mRNA expression of tolerogenic factors CCR7 and 
Foxp3. 
Figure 5. Cyclosporine A treatment decreased the loss of epithelium and the development of OAD in a 
dose-dependent fashion in allograft s . CsA was administered daily at a dose of 0, 1.0 or 1.5 mg/kg s.c. 
from the day of operation until sacrifi ce. For histological evaluation, tracheal sections of allograft s at 3 
and 10 days were stained with Mayer`s hematoxylin and eosin (H&E). Th e histological changes in the 
respiratory epithelium were evaluated as the percentage of circumference not covered by epithelium (A). 
Luminal occlusion was evaluated as the reduction in luminal area (B). Data is expressed as mean ± 
SEM. n=6 per group. *P<0.05. Modifi ed from study I.
4.  SimvastaƟ n treatment inhibited the development of 
obliteraƟ ve airway disease (study II)
First, we investigated whether simvastatin treatment inhibits the development of OAD 30 
days aft er transplantation and whether the eff ect is dose-dependent. In the treatment groups, 
simvastatin doses were 0.1, 0.5, 2, 5 or 20 mg/kg daily, with the treatment commenced on the 
day of transplantation and continued throughout the study. Simvastatin treatment in the 
absence of background immunosuppression failed to prevent the total loss of epithelium at 30 
days regardless of the dose. Th e lowest dose of simvastatin, 0.1mg/kg, had no eff ect on tracheal 
occlusion (Fig. 6A,C).
Simvastatin treatment with doses of 0.5, 2, 5, and 20 mg/kg daily attenuated tracheal occlusion at 
30 days, when compared to vehicle-treated controls (Fig. 6A,D-G) and this eff ect of simvastatin 
was not dose-dependent.
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Figure 6.  Simvastatin treatment inhibits the development of OAD. Heterotopic rat tracheal 
transplantation model. Allograft  recipients received simvastatin 0.1, 0.5, 2, 5 or 20 mg/kg or vehicle 
daily for a study period of 30 days. No immunosuppression was administered to avoid drug interactions. 
For histological evaluation tracheal sections were stained with Mayer`s hematoxylin and eosin (H&E). 
Luminal occlusion was evaluated as the reduction in luminal area (A). Illustrative photomicrographs of 
tracheal cross-sections (B-G), original magnifi cation x40. Data is expressed as mean +/- SEM. n=6 per 
group. * P<0.05. Modifi ed from study II.
5.  SimvastaƟ n treatment enhanced the proliferaƟ on and 
regeneraƟ on of the epithelium (study II)
Since the eff ect of simvastatin was dose-independent, for the second phase of the study we 
chose to investigate the benefi cial eff ects of the clinically relevant dose of 0.5 mg/kg/d and a 
supraclinical dose of 20 mg/kg/d of simvastatin at the 3 and 10 day time-points. Both doses 
delayed the development of OAD similarly in the fi rst phase of the study and we wanted to 
evaluate, if there were some diff erences in the mechanisms of epithelial recovery and in the 
immunological responses between these two doses.
Neither the lower nor the higher dose of simvastatin prevented the loss of epithelium due to 
ischemic injury at 3 days, but both doses enhanced epithelial recovery during the alloimmune 
response at 10 days (Fig. 7A). Immunohistochemical analysis revealed that early epithelial 
recovery was linked to a signifi cantly increased number of proliferating Ki-67+ cells in the 
tracheal epithelium in both groups at 3 days (Fig. 7B). 
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Figure 7.  Simvastatin treatment enhances the proliferation and regeneration of the epithelium in rat 
tracheal allograft s. Allograft  recipients received simvastatin 0.5 or 20 mg/kg or vehicle daily. Tracheal 
sections of allograft s at 3 and 10 days were stained with Mayer`s hematoxylin and eosin (H&E) for 
histologic evaluation and immunohistochemically for ki-67+ proliferating epithelial cells. Th e histological 
changes in the respiratory epithelium were evaluated as the percentage of circumference not covered by 
respiratory epithelium (A). Th e number of positively staining ki-67+ cells was counted as positive cells in 
the tracheal respiratory epithelial lining using x400 magnifi cation (B, grade; 0-3, 0 = no positive cells, 3 
= nearly all positive cells). Data is expressed as mean +/- SEM. n=6 per group. * P<0.05. Modifi ed from 
study II.
6.  SimvastaƟ n treatment inhibited adapƟ ve T cell alloimmune 
acƟ vaƟ on (study II)
Both doses of simvastatin markedly reduced IL-23 mRNA and lymphocyte chemokine CCL20 
production, and the infi ltration of CD4+ and CD8+ T cells into allograft s already at 3 days. At 
10 days, a time-point focused on the adaptive immune response phase, simvastatin signifi cantly 
attenuated the production of proinfl ammatory cytokines IL-1ß, TNF-α, MCP-1, and IP-10, 
as well as Th 17 polarizing cytokines IL-6 and IL-17e, and inhibited allograft  infi ltration by 
infl ammatory cells. However, we did not detect any major diff erences in the mRNA expression of 
chemokines or proinfl ammatory cytokines  between the two simvastatin doses at 3 and 10 days. 
7.  ProtecƟ ve eﬀ ects of simvastaƟ n on infl ammaƟ on and 
obliteraƟ ve airway disease were parƟ ally mediated through 
nitric oxide synthase (study II)
Some of the benefi cial eff ects of the statin therapy are mediated via induced NO-activity. 
Th erefore, in the third phase of the simvastatin study, L-NAME was used to inhibit NOS 
activity in simvastatin treated animals for a period of 30 days. We wanted to dissect whether the 
benefi cial eff ect of simvastatin therapy is NOS-dependent and again we chose to evaluate the 
same 3, 10, and 30 day time-points. Co-administration of L-NAME alongside with simvastatin 
markedly increased the loss of epithelium of the allograft s compared to the simvastatin-only 
therapy group at day 3. A total loss of epithelium was also seen in all L-NAME treated allograft s 
at 30 days. Co-administration of L-NAME with simvastatin resulted in a markedly increased 
development of luminal occlusion compared to simvastatin-only receiving animals at 30 days but 
did not negate the benefi cial eff ect entirely. 
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8. The development of obliteraƟ ve airway disease was delayed 
in mVHL-/- recipients of tracheal allograŌ s (study III)
Th e eff ect of HIF-1α on the development of OAD was investigated by studying HIF-1α 
upregulation (VHL-/-) and HIF-1α downregulation (HIF -/-) in monocyte/macrophages using 
recipients with HIF-1α or VHL gene deletion in the myeloid cell lineage. We chose to evaluate the 
same 3, 10, and 30 day time-points as in previous studies. We decided not to compare mHIF-1α-/- 
and mVHL-/- to each other, because mVHL-/- leads to stabilization of both HIF isoforms, HIF-1 
and HIF-2, but on the other hand,     mHIF-1α-/- leads only to HIF-1 defi ciency. At day 3, 
during the ischemic phase, all tracheal allograft s showed equally prominent respiratory epithelial 
cell injury (Fig. 8A). In mVHL-/- recipients, the epithelium was fully recovered at 10 days and 
remained partly preserved at 30 days (Fig. 8A), whereas a  total loss of epithelium was seen in 
mHIF-1α -/- recipients and in littermates (LM) at 30 days (Fig. 8A). In mVHL-/- recipients, the 
airway occlusion was signifi cantly decreased at 30 days in the absence of immunosuppression 
(Fig. 8B, E).
Figure 8. Development of OAD was delayed in mVHL-/-recipients (VHL-ko, knockout) of tracheal 
allograft s. Tracheal allograft s were heterotopically transplanted from Balb/C donors to MHC-
mismatched recipients with HIF-1 α (mHIF-1α-/-) or VHL (mVHL-/-) defi ciency in myelomonocytic cells. 
No immunosuppressive or any other treatment was given. Th e histological changes in the respiratory 
epithelium were evaluated as percentage of circumference not covered by respiratory epithelium (A). 
Airway occlusion was evaluated as the reduction in luminal area (B). Illustrative photomicrographs C-E 
(original magnifi cation x 80) stained with Mayer`s hematoxylin and eosin (H&E). Data is expressed as 
mean +/- SEM. n=6 per group. * P<0.05. mHIF-1α-/- and mVHL-/- were not compared to each other.
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9.  The infl ammatory response was reduced and T regulatory 
cell transcripƟ on factor was increased in tracheal allograŌ s in 
mVHL-/-recipients (study III)
Aft er the histological evaluation, we analysed the number of infl ammatory cells in the 
tracheal cross-sections at 3 and 10 days. Th ere was no diff erence between the three groups 
at day 3. However, the number of CD11b+ macrophages and CD4+ T cells was signifi cantly 
reduced in tracheal allograft s transplanted to mVHL-/- recipients at 10 days. Based on the 
histological and immunohistochemical results we decided to concentrate on mVHL-/- 
recipients to defi ne the mechanisms of the delayed OAD development. qRT-PCR analysis 
was performed from the tracheal samples at the peak of the alloimmune response at 10 
days. At that point, the mRNA expression of T regulatory cell transcription factor FoxP3 
was signifi cantly increased (Fig. 9A). Meanwhile, the mRNA expression of the Th 17 related 
cytokine IL-6 and of MCP-1 was signifi cantly reduced in mVHL-/- at the same time-point 
(Fig. 9B). 
   
Figure 9. Th e mRNA expression of T regulatory cell transcription factor (FoxP3) was increased in 
tracheal allograft s of mVHL-/-recipients (VHL-ko, knockout). Tracheal allograft s were heterotopically 
transplanted from Balb/C donors to MHC-mismatched recipients with HIF-1 α (mHIF-1α-/-) or VHL 
(mVHL-/-) defi ciency in myelomonocytic cells. No immunosuppressive or any other treatment was given. 
qRT-PCR analysis was performed from the tracheal samples 10 days aft er transplantation (A-B). Data is 
expressed as mean ± SEM. n=6 per group. * P<0.05.
10.  The development of OAD in tracheal allograŌ s was not 
alleviated in mHIF-a-/- recipients in the presence of T cell 
immunosuppression (study III)
In the second phase of our study, we investigated how changes in HIF-1 activity aff ect the 
development of OAD in tracheal allograft s in the presence of low-dose tacrolimus preventing T 
cell signal transduction and IL-2 production. In all allograft s, an almost total loss of epithelium 
was seen at 30 days despite immunosuppression. However, OAD in tracheal allograft s was 
signifi cantly increased in mHIF-1α-/- recipients compared to LMs at 30 days. Th ere was no 
diff erence in the degree of preserved epithelium or occlusion between mVHL-/- and LM.
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DISCUSSION
1.   Rat and mouse heterotopic allograŌ  models
According to Grossman and Shilling “the ideal model for studying lung alloreactivity would be 
one that is not technically prohibitive and that closely resembles both the natural pulmonary 
physiology, as well as pathophysiology of lung transplantation rejection both acute and 
chronic” (Grossman and Shilling 2009). Although new animal models of OB investigation are 
constantly being developed, an ideal model has not yet been presented (Grossman and Shilling 
2009). As an idea, murine orthotopic single LT model could be the solution for the problem. 
Both rat and mouse orthotopic lung transplant models have been developed (Matsumura et al. 
1995; Okazaki et al. 2007). Th e theoretical benefi ts of these models are clear. Th ere is airfl ow 
into the transplanted lung, the graft  is vascularized, and chronic lesions build up in the small 
airways during the follow-up (Matsumura et al. 1995). A single LT model in the mouse is a quite 
promising setup considering OB investigation (Okazaki et al. 2007) and it also allows diff erent 
knockout modifi cations. However, orthotopic lung transplantations are technically far more 
demanding procedures compared to other more simple models, especially in the mouse. Due 
to this,  the reproducibility of the OB lesions in both mouse and rat orthotopic lung transplant 
models is inconsistent (Hirschburger et al. 2007) and an orthotopic model over a major MHC 
mismatch is lacking. Additionally, chronic lesions seen in the graft s in the rat model are not 
typical OB lesions (Matsumura et al. 1995). Th erefore, we still lack the optimal experimental 
model for studying OB development.
Because the the simplicity, both the rat and mouse heterotopic tracheal allograft  models are 
widely used and accepted methods to investigate OAD. Th e use of these models has several 
advantages. Tracheal transplantation is technically a simple and reproducible method, and no 
baseline immunosuppession is required for the allograft s to survive (Hele et al. 2001). Unlike 
most orthotopic lung transplant models, our model is performed over a major MHC mismatch 
(Hertz et al. 1993; Hele et al. 2001).  In addition, allograft s develop obliterative changes in an 
accelerated fashion (Hertz et al. 1993; Koskinen et al. 1997) and results of previous studies using 
this model have many similarities with investigations in humans (Hele et al. 2001; McDyer 2007; 
Sato et al. 2009). However, pathological changes of human OB are not seen in large airways and 
there is no airfl ow in heterotopically transplanted rodent tracheas, which may aff ect the epithelial 
function and pathophysiology. Th e graft  circulation also diff ers from human lung allograft s. In 
this model, the capillary network develops into the graft  and the blood supply comes from the 
systemic circulation. Th erefore, the graft s develop adequate circulation early aft er transplantation 
(Hele et al. 2001; McDyer 2007). Furthermore, tracheal allograft s contain less lymphoid tissue, 
which may have an eff ect on immunogenicity. Th ese limitations must be kept in mind when 
extrapolating our results. Despite the model’s shortcomings many advantageous features of the 
heterotopic allograft  model favour its use in OB investigation, until a signifi cantly better model 
is presented. 
In our study we specifi cally brought out new features of the rat heterotopic allograft  model. Our 
results shed light on the mechanisms and relations of innate and adaptive responses and help us 
to better understand the development of OAD in this particular model. Better understanding of 
the model will allow us and other investigators to plan future experiments even more carefully. 
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In addition, we might be able to draw more accurate conclusions from the results of forthcoming 
studies. 
2.   Early ischemia and innate immune response in tracheal 
allograŌ s
Ischemia is currently unavoidable in transplantation procedures. Th e infl ammatory response 
to ischemia is predominantly an innate immune response (Carden and Granger 2000; Linfert 
et al. 2009). Innate immunity is a genetically programmed reaction to tissue injury and the 
magnitude of the response is defi ned by the prevailing microenvironment and extent of 
injury and/or pathogen load. In our study, ischemia-induced changes were similar in syn- and 
allograft s, suggesting alloantigen independency in early infl ammation and underlining the role 
of innate immune activation in the early postoperative period. Although we can control adaptive 
immune responses to a certain extent with our current immunosuppressive therapies, we have 
very little control over innate immunity. On the other hand, the suppression of innate immunity 
also could attenuate the adaptive immune response and the development of CLAD. Due to the 
nature of transplant surgery, it is unlikely that one can totally prevent the expression of PRR 
ligands (PAMPs and DAMPs) during tissue injury. However, decreasing the activation and 
downstream signaling of PRRs might reduce innate immune responses. In our study, an increase 
in the mRNA levels of TLR2, a well described PRR (Barton and Medzhitov 2003), was seen in the 
syngraft s early aft er transplantation. Prevention of TLR activation could have an impact on the 
innate immune response. Nowadays, the investigation of TLR signaling pathways is highly active 
in the fi eld of cancer research, as TLRs are reported to have both stimulatory and inhibitory 
eff ects in the development of malignancies (Wang et al. 2014). However, these mechanisms are 
not yet fully understood and further investigation of innate immunity activation is needed. Th e 
aim is to be able to manipulate TLR signaling pathways in a controlled matter. Regulation of 
MyD88, a key TLR signal adaptor could be one option. According to Walker et al., the absence of 
MyD88 reduces the adaptive immune response (Walker et al. 2006). On the other hand, reduced 
innate response might also be achieved with selective inhibition of TLR4-mediated cytokine 
production, including TNF-α and IL-6 (Li et al. 2006).
Although syngraft s showed severe epithelial injury and innate immune activation early aft er 
transplantation in our study, they recovered completely. It is likely that the absence of alloantigens 
guided the diff erentiation of naïve T cells towards a more regulatory phenotype in syngraft s 
compared to allograft s. Th e observed increase in the mRNA expression of Treg-related FoxP3, 
IL-10, and TGF- in syngraft s supports this hypothesis. Eventually, the regulatory response 
led to cessation of infl ammation and allowed regeneration of the tracheal epithelium. On the 
other hand, in the presence of alloantigens, early ischemic injury and innate immune response 
were followed by robust adaptive immune responses in the allograft s. In this model, the early 
ischemic injury is very extensive and not aff ected by our immunosuppressive therapies (Hertz 
et al. 1993, Hele et al. 2001, study I). Th e fate of the syn- and allograft s is highly predictable and 
as mentioned before, very reproducible. Due to these facts, the benefi cial eff ects of any pre-, 
intra-, or early postoperative therapeutical method or agent can very likely be detected in the 
transplanted graft s. Th erefore this model seems to be useful also in the future for investigating 
the control of the innate immune response.
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3.  AdapƟ ve immune responses and the development of 
obliteraƟ ve airway disease
Th e innate immune response is not usually able to reject an allograft  on its own and adaptive 
immune activation is required. In our study, the presence of foreign antigens in the allograft s 
subsequently led to increased mRNA expression of proinfl ammatory cytokines as well as 
increased infl ux of infl ammatory cells. Th ese actions were followed by Th 17 activation 
leading eventually to a sustained Th 1 immune response. Th is was accompanied by infi ltration 
of the allograft  with proinfl ammotory eff ector cells that target the tracheal epithelium and 
contribute to epithelial injury. Th is is probably one of the most important initial events in the 
development of OAD (Yousem et al. 1996). Th e activation of adaptive immune responses also 
seems to increase tolerogenic activity in the allograft s. Increased Foxp3 expression has been 
observed in endomyocardial biopsies of heart transplant patients as well as in the urine of 
kidney transplant patients suff ering from acute rejection (Muthukumar et al. 2005; Dijke et al. 
2007). Increased Treg activity may therefore be a sign of a systemic regulatory response against 
overactive infl ammation. However, the proinfl ammatory cytokine milieu was more dominant in 
allograft s compared to syngraft s in our study and probably overrode the regulatory component. 
Continuous alloimmune response led to irreversible epithelial injury followed by progressive 
fi broproliferation and eventually total occlusion of the tracheal lumen. 
Most of the present immunosuppressive medication is targeted on the suppression of adaptive 
immune responses. Cyclosporine A inhibits T cell activation and proliferation. In our present 
study, CsA treatment prevented the development of OAD in a dose-dependent fashion, as 
previously shown (Koskinen et al. 1997, study I). Furthermore, CsA suppressed Th 1, Th 2 and 
Th 17 responses. Since high doses of CsA can prevent OAD in this model, the T cell-mediated 
alloimmune activation is central for OAD development in this setting. It should be noted that 
CsA trough levels required to prevent OAD in our model are above 350 ng/ml (Koskinen et al. 
1997), which is a toxic level in humans. CsA also prevented the tolerogenic signaling of T cells 
and this may be one of the reasons why despite enabling lung transplantation and preventing 
acute rejection, CsA-based immunosuppression has not aff ected the development of CLAD. 
CsA has also been linked to increased expression of the innate immune activators TLR2 and 4 
(Lim et al. 2005). In our study, no apparent eff ect on innate immune activity was observed with 
CsA treatment. However, we did not observe any signifi cant diff erences between innate immune 
activation of syn- or allograft s. It is also unlikely that CsA could modulate the very early innate 
immune activation in the allograft s in this model as there is no proper circulation in the allograft  
for the fi rst 2-3 days aft er transplantation (Hele et al. 2001). 
4.  SimvastaƟ n treatment and the development of obliteraƟ ve 
airway disease
Previous reports state that statins have diff erent anti-infl ammatory eff ects in a murine model 
of allergic asthma and emphysema (McKay et al. 2004; Lee et al. 2005). Statins have important 
vasculoprotective and immunomodulatory properties (Bonetti et al. 2003; Wang et al. 2008). 
Especially, statins are reported to have lots of highly varied anti-infl ammatory eff ects, i.e., 
inhibition of cell adherence and movement, T-cell proliferation and alteration of cytokine 
production (Johnson et al. 2003). Th ey also inhibit MHC class II expression and downregulate 
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alloantigen responses (Robertson et al. 2009). According to these reports, statins attenuate the 
innate immune response in tissue injury. However, there is only scarce data on statin treatment 
and lung transplantation at the moment. A previous retrospective study by Johnson et al. showed 
that patients treated with statins had better survival rates and less OB than patients who were 
not on statin therapy. However, this was not a controlled study but rather a retrospective analysis 
(Johnson et al. 2003). Th e possible role and mechanisms of action of statins in the prevention of 
OB remain unclear.
Due to the severe ischemic tracheal graft  injury, there is an intense innate response in this 
model, as described earlier. Although statins do not reduce IRI in our model, we can investigate 
the changes in the subsequent infl ammatory activation. It has been reported that simvastatin 
downregulates the epithelial release of proinfl ammatory and airway remodeling factors, which 
contribute to the airway injury (Murphy et al. 2008). In our study, simvastatin treatment led 
to increased regeneration of epithelium in the allograft s. Statins are also reported to have 
vasculoprotective properties, which preserve the stability of endothelial cytoskeleton and 
decreased microvascular permeability and leucocyte extravasation (Lee et al. 2004; Tuuminen 
et al. 2013). Th ese benefi cial eff ects might explain why simvastatin inhibited allograft  infi ltration 
of macrophages, and dendritic cells, and also the expression of lymphocyte chemokine and 
proinfl ammatory cytokine mRNA in the allograft s, referring to a decreased innate immune 
response. Probably due to this, reduced numbers of CD4+ and CD8+ T cells and an inhibition 
of the adaptive immune response were detected and the development of OAD was delayed. 
According to our results, simvastatin seems to regulate the adaptive immune activation via a 
reduced innate immune response. According to Watts et al., statins also reduce growth factor 
expression in a fi broblast model and this may have an eff ect on airway remodelling (Watts et al. 
2005). However, we did not detect any benefi cial eff ect of simvastatin on the mRNA expression 
of fi brosis related growth factors.  
In our study, the eff ect of simvastatin was partially mediated by increased NO-activity. 
Restoration of NO-activity has been shown to eff ectively inhibit smooth muscle cell proliferation 
in models of pulmonary hypertension (Zuckerbraun et al. 2010)) and we previously reported that 
upregulation of NO production by L-arginine resulted in reduced OAD (Kallio et al. 1997). Th us, 
it is likely that simvastatin may also have inhibited smooth muscle cell proliferation through 
induction of NO-activity in our study. Th is is supported by our fi nding that statins reduced 
tracheal luminal obliteration even at later stages when total loss of epithelium was observed. 
L-NAME-mediated NOS inhibition resulted in accelerated epithelial loss in simvastatin-treated 
animals. Th is suggests that simvastatin promotes epithelial function at least partially through 
induction of NO-activity.
Preserved epithelium was linked to inhibition of OAD development in the heterotopic tracheal 
allograft  model (Koskinen et al. 1997). Th e delayed loss of epithelium in the simvastatin group 
probably slowed down the fi broproliferative response and thereby the development of OAD 
in our study. However, although our results are promising, simvastatin treatment could only 
delay OAD development. Since no epithelium was left  in the allograft s at 30 days, it is clear 
that the simvastatin-treated allograft s would eventually have become totally occluded. An 
important fi nding of our study was that simvastatin inhibited the development of OAD without 
any background immunosuppression. Th is is a highly relevant issue considering the strong 
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alloimmune response which develops in the heterotopic allograft  model in fully-mismatched 
animals (Hertz et al. 1993). While simvastatin treatment alone is not suffi  cient to prevent OAD, 
our results suggest that lung transplant recipients may benefi t from the pleiotropic eff ects of 
statin treatment. As we already have some evidence of the benefi cial eff ect of statins aft er lung 
transplantation (Johnson et al. 2003) further clinical studies with statins should be planned. 
Furthermore, a decreased innate response in the lung transplant could prevent initial graft  injury 
and thereby adaptive immune activation. Earlier, pravastatin was shown to increase early survival 
aft er orthotopic lung transplantation (Li et al. 2006). In addition, anti-infl ammatory eff ects of 
statins could have an impact on the decrease of acute rejection episodes in the follow-up. 
In clinical use, simvastatin and other statins have less severe adverse eff ects than traditional 
immunosuppressive drugs. According to our results and other evidence mentioned earlier, it 
may be possible that simultaneous use of statin aft er transplantation could also reduce the need 
of immunosuppression in humans. For these reasons, the role of statin therapy in lung transplant 
patients should be re-evaluated. Furthermore, preoperative donor treatment with statins was 
shown to decrease IRI, adaptive immune activation, and cardiac allograft  vasculopathy in 
experimental heart transplantation (Tuuminen et al. 2011). Th is eff ect should be investigated 
in the context of lung transplantation using an orthotopic lung transplant model well-suited for 
IRI-studies. Th is would enable studying diff erent statins and determining which statin has the 
best therapeutic profi le or whether there is a class eff ect. Given the well-known safety profi le 
and inexpensive cost of statins, translational clinical trials are also highly feasible. In order to 
assess whether donor statin therapy reduces IRI aft er transplantation, our program has already 
initiated a prospective randomized study of donor statin therapy in heart, lung, liver, and 
kidney transplantation with the title “Th e impact of donor statin therapy on the development 
of infections and chronic rejection” (Donor Simvastatin Treatment in Organ Transplantation 
(SIMVA), ClinicalTrials.gov Identifi er: NCT01160978).
5.  HIF-1 overexpression in recipient myelomonocyƟ c cells 
increases tolerogenic T-cell acƟ vity
In our study, we show that constant activity of HIFs in myelomonocytic cells of the recipients 
reduced infl ammation in the allograft s in otherwise non-immunosuppressed recipients. Th is 
result was somewhat surprising as prior reports have implicated a central role for HIF-1 in 
promoting infl ammation (Cramer et al. 2003, Anand et al. 2007, Nizet and Johnson 2009). One 
possible mechanism of action by which HIF-1 overexpression reduced infl ammation might have 
been due to increased tolerogenic T-cell activity. In our study, mVHL-/- allograft s showed signs of 
increased FoxP3 activity implying tolerogenic Treg activation. Increased FoxP3 expression was 
also observed in recipients’ spleens, suggesting increased Treg activity in the secondary lymphoid 
organs. We also observed reduced mRNA expression of IL-6 in mVHL-/-allograft  recipients. IL-6 
is a potent inhibitor of TGF- driven induction of CD4+ FoxP3+ regulatory T cells (Bettelli et 
al. 2006). Interestingly, we also noticed reduced mRNA expression of IL-6 and simultaneously 
increased mRNA expression of FoxP3 in mVHL-/- allograft s in our study. Furthermore, reduced 
mRNA expression of MCP-1 and reduced allograft  infi ltration of infl ammatory cells into the 
allograft  was seen. Altogether these results suggest a decreased adaptive immune response in 
mVHL-/- and T regulatory pathway activation in these allograft s at 10 days. Ben-Shoshan et al. 
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recently reported that hypoxia controls Treg homeostasis via HIF-1(Ben-Shoshan et al. 2008). 
Th e number as well as the potency of Tregs are also enhanced in hypoxia (Ben-Shoshan et al. 
2008). In our study, VHL-defi ciency in the myeloid cells may have resulted in increased Treg 
activity leading to reduced infl ammatory and immune responses. Th erefore it seems that the 
fi nal eff ect of HIF-1 in any one setting is likely dependent on the prevailing microenvironment. 
Th e potential protective role of HIF-1 is tempting as the HIFs are major regulators of the cellular 
response to hypoxia. A targeted control of protective properties of HIFs could reduce ischemic 
injuries of the organs, especially during a transplant operation.
6.  Hypoxia-inducible factor-1 in recipient myelomonocyƟ c 
cells delays obliteraƟ ve airway  disease in mouse tracheal 
allograŌ s
In addition to increased tolerogenic activity, there is another mechanism through which 
HIF-1 may have reduced infl ammation and thereby the development of OAD in our study. 
Th e diff erence between mVHL-/-and mHIF-/- animals was still evident when tacrolimus was 
administered suggesting that tacrolimus treatment did not abrogate the benefi cial eff ects of 
myelomonocytic overexpression of HIF-1. HIF-1 overexpression was associated with a lesser 
degree of epithelial loss at 10 days in the allograft s. As the rate of epithelial loss was similar 
in all allograft s early aft er transplantation, it is unlikely that early epithelial injury due to 
ischemia was aff ected by myeloid cell HIF-1 expression. It is more likely that the reduced 
infl ammatory response allowed better epithelial regeneration in tracheal allograft s. Allograft  
overexpression of HIF-1 is reported to promote repair of airway microvasculature through 
the induced expression on pro-angiogenic factors in mice (Jiang et al. 2011). Reduced 
epithelial injury could explain the delay in OAD development as we know the importance of 
a proper epithelium during this process (Neuringer et al. 2002). 
It should be noticed, that mVHL-/- leads to stabilization of both HIF isoforms, HIF-1 and 
HIF-2(Krieg et al. 2000). However, we did not dissect which one of the isoforms is responsible 
for the benefi cial eff ect. It has been shown that both macrophages and neutrophils are able to 
express both HIF-1 and HIF-2 (Poitz et al. 2014; Th ompson et al. 2014). However, as the OAD 
development was signifi cantly accelerated in mHIF-1-/-recipients one may assume that HIF-1 
activity was the major contributor to the decreased OAD development in mVHL-/- recipients. In 
addition, it has been reported that HIF-2regulates mainly key neutrophil functions (Th ompson 
et al. 2014), but we did not detect any signifi cant diff erence in the number of MPO+ neutrophils 
between the groups at 3 or 10 days in our study.
 Again, as in our simvastatin study, without any co-administered immunosuppressant it is only 
possible to slow down the development of OAD by infl uencing HIF-1 stability. Our results 
support a role for HIF-1 in alleviating early allograft  injury and infl ammation and a possible 
novel therapeutic target in preventing OAD.
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STUDY LIMITATIONS
Both tracheal allograft  models used in our study have several limitations that should be 
considered when interpreting the results. Th e transplantation was performed over a full MHC 
mismatch and no immunosuppression was used making this a very robust model and the 
ensuing loss of epithelium and OAD development were much more accelerated compared to the 
clinical setting.
Additionally, in this study we used knockout animals with HIF-1α or VHL defi ciency in 
myelomonocytic cells. However, one should keep in mind, that while the majority of the 
myelomonocytic cells has a targeted deletion, the deletion effi  ciency of HIF-1α or VHL is not 
perfect (Cramer et al. 2003). Finally, we focused on the RT-PCR analysis of mRNA levels in 
tissue samples in all three studies. However, the mRNA analysis gives insight only to current 
cellular activity and does not necessarily refl ect protein expression. Th e mRNA analysis also 
gives little information regarding the already synthesized intracellular proteins, their deposition 
and release. RT-PCR analysis was chosen, because it is the most standardized method in analysis 
of mRNA levels in our laboratory and it also off ers the broadest analysis repertory of diff erent 
factors in our hands.
Study Limitations
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CONCLUSIONS OF THE STUDY
Firstly, simvastatin treatment enhanced early epithelial recovery aft er transplantation and 
inhibited allograft  infi ltration of infl ammatory cells and expression of lymphocyte chemokine 
and proinfl ammatory cytokine mRNA. Importantly, simvastatin inhibited the development of 
OAD (II).
Secondly, continuous HIF-1 expression in myeloid cells improved epithelial recovery, reduced 
infl ammatory cell accumulation, and increased regulatory FoxP3 mRNA expression in mouse 
tracheal allograft s. Importantly, these eff ects led to better preservation of tracheal epithelium and 
a decrease in the development of OAD. All these benefi cial eff ects were observed without any 
immunosuppression. Our results suggest that HIF-1 has a protective role in preventing OAD in 
an experimental model for lung transplantation (III).
Finally, our fi ndings here show that the activation of innate immune responses by early ischemia 
takes place in both syngraft s and allograft s in the rat heterotopic allograft  model. However, in 
the presence of alloantigens, early ischemic injury induced both innate and adaptive immune 
responses which were followed by Th 17 activation and aft erwards by a sustained Th 1 immune 
response. Th is was accompanied by infi ltration of the allograft  with proinfl ammatory eff ector 
cells that target the tracheal epithelium leading to progressive fi broproliferation and total tracheal 
occlusion if left  untreated. Th e increased knowledge on early mechanisms of immune activation 
enables future studies that aim at interrupting the molecular pathways leading to alloimmune 
activation and OAD (I).  
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YHTEENVETO ΈFINNISH SUMMARYΉ
Keuhkonsiirto on loppuvaiheen keuhkosairauksissa, kuten keuhkoahtaumataudissa, ainoa 
käytettävissä oleva parantava hoitomuoto. Vaikka keuhkonsiirtopotilaiden lyhytaikaisennuste 
on jatkuvasti parantunut uusien lääkkeiden, kehittyneen kirurgisen tekniikan ja tehohoidon 
myötä, pitkäaikaisennustetta heikentää keuhkosiirrännäisen krooninen toimintahäiriö. Sen 
alamuodoista bronchiolitis obliterans-syndrooma eli BOS on parhaiten tunnettu muoto. 
Kudostasolla pienissä keuhkoputkissa on jatkuva tulehdustilanne, jonka seurauksena pienet 
hengitystiet lopulta ahtautuvat lisääntyneen sidekudoskasvun seurauksena ja potilaan 
suorituskyky heikkenee merkittävästi. BOS diagnosoidaan kliinisin löydöksin. Diagnoosi 
voidaan tehdä, jos keuhkonsiirteen toiminta selvästi heikkenee ilman muuta selittävää syytä. 
BOS on merkittävin syy keuhkonsiirteiden tuhoutumisiin ja potilaiden kuolemiin ensimmäisen 
vuoden jälkeen siirtoleikkauksesta. Vaikka kokemus hyljintälääkityksestä lisääntyy jatkuvasti 
ja uusia lääkkeitä on otettu käyttöön, ei tällä hetkellä kroonisen toimintahäiriön kehittymistä 
pystytä kuitenkaan juurikaan estämään, eikä ilmatiemuutoksia parantavasti hoitamaan. 
Keuhkonsiirtoleikkaus johtaa synnynnäisen immuniteetin aktivaatioon. Synnynnäinen 
immuniteetti on tärkeässä roolissa myös hankitun immuniteetin aktivaation käynnistymisessä. 
Tämä aktivaatio johtaa keuhkosiirteen akuuttiin hylkimisreaktioon. Toistuvat akuutit 
hylkimisepisodit voivat lopulta aiheuttaa kroonisen toimintahäiriön ja BOS:in kehittymisen. 
Nykyisillä hylkimisenestolääkkeillä pystytään lähinnä estämään/rauhoittamaan hankitun 
immuniteetin aktivoitumista, mutta valitettavasti tämä ei riitä estämään siirteen kroonista 
toimintahäiriötä. 
Tässä väitöskirjatutkimuksessa selvitimme keuhkonsiirtoa simuloivalla koe-eläinmallilla, 
vähentääkö erilaisin keinoin saavutettava synnynnäisen immuniteetin aktivaation esto 
sidekudoskasvua rotan ja hiiren henkitorvisiirteissä. Käyttämässämme koe-eläinmallissa 
siirretään pala luovuttajaeläimen henkitorvea hiiren ihonalaiskudokseen tai rotan vatsa-paidan 
sisään. Siirtoleikkauksen jälkeen siirteet kärsivät vaikeasta hapenpuutteesta, ennenkuin niihin 
kehittyy hiussuonten avulla verenkierto noin kolmen vuorokauden sisällä. Tutkimuksemme 
ensimmäisessä vaiheessa totesimme, että sekä syngeenisiin että allogeenisiin henkitorvisiirteisiin 
kehittyi merkittävä epiteelivaurio ja synnynnäinen immuniteetti aktivoitui. Syngeenisissä 
siirteissä tulehdustilanne kuitenkin rauhoittui nopeasti antigeenien puuttuessa ja suojaavien 
regulatoristen T-solujen aktivoituessa. Henkitorvisiirteen epiteelivaurio korjautui täysin ja 
siirteisiin ei kehittynyt lainkaan sidekudoskasvua. Allogeenisissa siirteissä sen sijaan kehittyi myös 
voimakas hankittu immuniteettireaktio, joka johti etenevään sidekudoksen muodostumiseen 
ja lopulta siirteen tukkeutumiseen sidekudoskasvun seurauksena. Mielenkiintoinen löydös 
tutkimuksemme toisessa vaiheessa oli, että tässä koe-eläinmallissa lähinnä kolesterolilääkkeenä 
tunnettu simvastatiini päivittäin annosteltuna vähensi alkuvaiheen tulehdusreaktiota ja näin 
hidasti sidekudoksen kasvua henkitorvisiirteissä. Merkittäväksi tuloksen tekee se seikka, että 
koe-eläimet eivät saaneet minkäänlaista hylkimisenestolääkitystä simvastatiini-hoidon ohessa.
Hapenpuutteessa soluissa aktivoituvat HIF-trankriptiotekijät (hypoxia inducible factors). HIF-1 
vastaa useista solujen toiminnoista, joita tarvitaan niukkahappisessa ympäristössä. Tämän 
lisäksi HIF-1 on osallisena säätelemässä myeloisten solujen toimintaa tulehdusreaktiossa. 
Yhteenveto (Finnish Summary)
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Toiminta voi tilanteesta riippuen olla luonteeltaan tulehdusta kiihdyttävää tai rauhoittavaa. 
Tutkimuksemme kolmannessa vaiheessa meillä oli käytössämme geenimuunneltuja hiiriä, joilla 
oli myeloisissa soluissa jatkuva HIF-1 aktivaatio. Samaa koe-eläinmallia käyttäen teimme näille 
geenimuunnelluille hiirille henkitorvisiirtoja. Jatkuva HIF-1 aktivaatio hidasti sidekudoskasvua 
siirteissä kontrollisiirteisiin verrattuna ja sillä oli siis siirteitä suojaava vaikutus tässä mallissa. 
Tutkimuksemme tulokset viittaavat siihen, että keuhkonsiirteen alkuvaiheen hapenpuutteesta 
johtuva vaurio ja sitä seuraava synnynnäisen immuniteetin aktivaatio ovat merkittäviä syitä 
myöhemmin ilmaantuvan keuhkoputkia ahtauttavan sidekudoskasvun kehittymisessä. Statiini-
lääkityksen mahdollinen hyöty keuhkonsiirtopotilaita hoidettaessa tulisi myös arvioida 
uudelleen. Lisäksi näissä tutkimuksissa käyttämämme keuhkonsiirtomalli koe-eläimillä 
vaikuttaa olevan edelleen hyvinkin käyttökelpoinen siihen asti, kunnes merkittävästi parempi 
keino hyljinnän tutkimiseen kehitetään.
Yhteenveto (Finnish Summary)
47
ACKNOWLEDGEMENTS
Th is study was carried out in the Transplantation Laboratory, University of Helsinki and Helsinki 
University Central Hospital. 
 
I wish to express my sincere gratitude to everyone who has contributed to this Th esis in any way. 
Especially I would like to thank: 
My supervisor, Professor Karl Lemström for the opportunity to join to your excellent group and 
your continuous support on this rather long path. Aft er all these years I am still amazed at your 
endless enthusiasm for transplantation immunology and search for the groundbreaking KBL-1 
molecule.
My other supervisor, Docent Jussi  Tikkanen, for your excellent guidance and support during 
these past years, and for your friendship. I really admire your clear visions and ability to 
summarize complicated entities. We have attended all the same schools since the second grade 
of elementary school, then the military service and now we have been in the same lab. Hopefully 
our “journey” will also continue in the coming years, too. 
Th e Reviewers of this work appointed by Th e Faculty of Medicine, University of Helsinki, 
Professor Hannu Jalanko and Associate Professor Göran Dellgren for your advice and comments 
in a very timely manner.
Dean of the Faculty of Medicine, Professor Risto Renkonen, Head of the Transplantation 
Laboratory, and Professor Emeritus Pekka Häyry, former Head of the Transplantation Laboratory, 
for providing excellent research facilities for this study.
Antti Nykänen, a friend from medical school, a member of our group, and colleague in our 
clinic. Your patience and support has been extremely important when I have been frustrated 
with the complexities in basic science and immunology. 
My co-authors and members of our group, Alireza Raissadati, Rainer Krebs, Raimo Tuuminen, 
Simo Syrjälä, and Mikko Keränen. Your help with the basic science, writing, computers and 
computer programs has been invaluable. Without this team, I could not have made it.  
Eeva Rouvinen for your excellent technical assistance and the large amount of work you have put 
in this study. Without your help my study would not have been started at all.
Leena Saraste for help with all the practical problems and the English language.
Th e staff  and colleagues of the Transplantation Laboratory for all their support and help.
Eija Saimanen, Veli-Matti Puolakka, Kari Teittinen, and Jarkko Ylinen for the guidance during 
my training years in Lappeenranta and Vaasa.
Acknowledgements
48
All my “senior” colleagues and principal chiefs in our clinic, especially Ulla-Stina Salminen, 
Kalervo Werkkala, Jarmo Salo, Eero Sihvo, Antero Sahlman, and Leo Ihlberg for the guidance in 
general thoracic and cardiac surgery and also for the fl exibility to arrange time for the scientifi c 
studies.
My “junior” colleagues Janne Jokinen and Juha Kauppi for your help and friendship during our 
specialization in cardiothoracic surgery. 
Hannu Hallikas, Juha Nissinen, and Markku Kaarne. You have been tremendous tutors/mentors/
guides during my surgical career. Your guidance and endless patience with my everlasting 
training progress in and out of the operating room have made a deep impact on my surgical 
skills, the way of surgical thinking and working ethics. 
My parents for your support and for my existence in this world, and especially my baby brother 
Antti, the leading scientist in our family.  I`m trying to follow your path and also pursue for 
astonishing achievements in the fi eld of excellence.
My friends and former teammates Rautsi, Joa, Laba, Jussi, Vila, Pate, Henkku, Ake, RaMi, and 
others for all the extracurricular activities and for not being overly enthusiastic about medicine, 
science and academic degrees. You have helped to set the focus of Th e Whip right.
And fi nally, Ulla & Th e Boys, you are the best!   
Financial support for this study was received from Helsinki University Hospital Research Funds, 
the Sigrid Juselius Foundation, the Academy of Finland, the Research and Science Foundation 
of Farmos, Th e Paulo Foundation, Jalmari and Rauha Ahokas Foundation, Aarne Koskelo 
Foundation, Päivikki and Sakari Sohlberg Foundation, Jane and Aatos Erkko Foundation, the 
Finnish Medical Society Duodecim, Orion Research Foundation, Finnish Transplantation 
Society, Finnish Society for Angiology, and the University of Helsinki. 
In Helsinki, November 2015
Acknowledgements
49
REFERENCES
Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 
2000 Aug 17;406(6797):782-7.
Afzali B, Lombardi G, Lechler RI. Pathways of major histocompatibility complex allorecognition. 
Curr Opin Organ Transplant. 2008 Aug;13(4):438-44.
Afzali B, Lombardi G, Lechler RI, Lord GM. Th e role of T helper 17 (Th 17) and regulatory T cells 
(Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol. 2007 
Apr;148(1):32-46. Review.
Ahmad T, Mabalirajan U, Sharma A, Aich J, Makhija L, Ghosh B, Agrawal A. Simvastatin improves 
epithelial dysfunction and airway hyperresponsiveness: from asymmetric dimethyl-arginine to 
asthma. Am J Respir Cell Mol Biol. 2011 Apr;44(4):531-9.
Ailawadi G, Smith PW, Oka T, Wang H, Kozower BD, Daniel TM, Kron IL, Jones DR. Eff ects of 
induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival 
aft er lung transplantation. J Th orac Cardiovasc Surg. 2008 Mar;135(3):594-602.
Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006 Feb 
24;124(4):783-801.
Anand RJ, Gribar SC, Li J, Kohler JW, Branca MF, Dubowski T, Sodhi CP, Hackam DJ. Hypoxia 
causes an increase in phagocytosis by macrophages in a hif-1alpha-dependent manner. Journal of 
leukocyte biology 2007;82:1257-1265.
Babu AN, Murakawa T, Th urman JM, Miller EJ, Henson PM, Zamora MR, Voelkel NF, Nicolls MR. 
Microvascular destruction identifi es murine allograft s that cannot be rescued from airway fi brosis. 
J Clin Invest. 2007 Dec;117(12):3774-85. 
Bando K, Paradis IL, Komatsu K, Konishi H, Matsushima M, Keena RJ, Hardesty RL, Armitage JM, 
Griffi  th BP. Analysis of time-dependent risks for infection, rejection, and death aft er pulmonary 
transplantation. J Th orac Cardiovasc Surg. 1995 Jan;109(1):49-57
Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science. 2003 Jun 6;300(5625): 
1524-5.
Belperio JA, Lake K, Tazelaar H, Keane MP, Strieter RM, Lynch JP 3rd. Bronchiolitis obliterans 
syndrome complicating lung or heart-lung transplantation. Semin Respir Crit Care Med. 2003 
Oct;24(5):499-530.
Ben-Shoshan J, Maysel-Auslender S, Mor A, Keren G, George J. Hypoxia controls cd4+cd25+ 
regulatory t-cell homeostasis via hypoxia-inducible factor-1alpha. European journal of immunology 
2008;38:2412-2418.
Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal 
developmental pathways for the generation of pathogenic eff ector th17 and regulatory t cells. 
Nature 2006;441:235-238.
Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin eff ects beyond lipid lowering--are they clinically 
relevant? Eur Heart J 2003;24:225-48.
Botha P, Archer L, Anderson RL, Lordan J, Dark JH, Corris PA, Gould K, Fisher AJ. Pseudomonas 
aeruginosa colonization of the allograft  aft er lung transplantation and the risk of bronchiolitis 
obliterans syndrome. Transplantation. 2008 Mar 15;85(5):771-4. 
Botha P, Fisher AJ, Dark JH. Marginal lung donors: A diminishing margin of safety? Transplantation. 
2006 Nov 27;82(10):1273-9.
References
50
Bruning U, Fitzpatrick SF, Frank T, Birtwistle M, Taylor CT, Cheong A. NFκB and HIF display 
synergistic behaviour during hypoxic infl ammation. Cell Mol Life Sci. 2012 Apr;69(8):1319-29
Burlingham WJ, Love RB, Jankowska-Gan E, Haynes LD, Xu Q, Bobadilla JL, Meyer KC, Hayney MS, 
Braun RK, Greenspan DS, Gopalakrishnan B, Cai J, Brand DD, Yoshida S, Cummings OW, Wilkes 
DS. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis 
in human lung transplants. J Clin Invest. 2007 Nov;117(11):3498-506.
Burton PR, Button B, Brown W, Lee M, Roberts S, Hassen S, Bailey M, Smith A, Snell G. Medium-
term outcome of fundoplication aft er lung transplantation. Dis Esophagus. 2009;22(8):642-8. 
Calzada MJ, Esteban MA, Feijoo-Cuaresma M, Castellanos MC, Naranjo-Suárez S, Temes E, Méndez 
F, Yánez-Mo M, Ohh M, Landázuri MO. von Hippel-Lindau tumor suppressor protein regulates 
the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-
independent mechanisms. Cancer Res. 2006 Feb 1;66(3):1553-60.
Cantu E 3rd, Appel JZ 3rd, Hartwig MG, Woreta H, Green C, Messier R, Palmer SM, Davis RD Jr. J. 
Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft  dysfunction 
in patients with gastroesophageal refl ux disease. Ann Th orac Surg. 2004 Oct;78(4):1142-51.
Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. J Pathol. 2000 
Feb;190(3):255-66.
Carroll MC. Th e complement system in regulation of adaptive immunity. Nat Immunol. 2004 
Oct;5(10):981-6. Review.
Chadha R, Heidt S, Jones ND, Wood KJ. Th 17: contributors to allograft  rejection and a barrier to the 
induction of transplantation tolerance? Transplantation. 2011 May 15;91(9):939-45.
Chang AC, Orens JB. Are there more lungs available than currently meet the eye? Am J Respir Crit 
Care Med. 2006 Sep 15;174(6):624-5
Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D; ISHLT Working Group on Primary Lung 
Graft  Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft  Dysfunction part II: 
defi nition. A consensus statement of the International Society for Heart and Lung Transplantation. 
J Heart Lung Transplant. 2005 Oct;24(10):1454-9.
Christie JD, Edwards LB, Aurora P, Dobbels F, Kirk R, Rahmel AO, Taylor DO, Kucheryavaya AY, 
Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty-fi ft h 
offi  cial adult lung and heart/lung transplantation report--2008. J Heart Lung Transplant. 2008 
Sep;27(9):957-69. 
Christie JD, Kotloff  RM, Ahya VN, Tino G, Pochettino A, Gaughan C, DeMissie E, Kimmel SE. Th e 
eff ect of primary graft  dysfunction on survival aft er lung transplantation. Am J Respir Crit Care 
Med. 2005 Jun 1;171(11):1312-6.
Christie JD, Edwards LB, Kucheryavaya AY, Aurora P, Dobbels F, Kirk R, Rahmel AO, Stehlik J, 
Hertz MI. Th e Registry of the International Society for Heart and Lung Transplantation: twenty-
seventh offi  cial adult lung and heart-lung transplant report--2010. J Heart Lung Transplant. 2010 
Oct;29(10):1104-18.
Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Kirk R, Rahmel AO, Stehlik J, 
Hertz MI. Th e Registry of the International Society for Heart and Lung Transplantation: Twenty-
eighth Adult Lung and Heart-Lung Transplant Report--2011. J Heart Lung Transplant. 2011 
Oct;30(10):1104-22. 
Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, Kirk R, Rahmel 
AO, Stehlik J, Hertz MI; International Society of Heart and Lung Transplantation. Th e Registry 
of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung 
transplant report-2012. J Heart Lung Transplant. 2012 Oct;31(10):1073-86.
References
51
Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. Conditional gene targeting in macrophages 
and granulocytes using lysmcre mice. Transgenic Res 1999;8:265-277.
Colvin RB, Smith RN. Antibody-mediated organ-allograft  rejection. Nat Rev Immunol. 2005 
Oct;5(10):807-17. 
Cooper JD, Billingham M, Egan T, Hertz MI, Higenbottam T, Lynch J, Mauer J, Paradis I, Patterson 
GA, Smith C, et al. A working formulation for the standardization of nomenclature and for 
clinical staging of chronic dysfunction in lung allograft s. International Society for Heart and Lung 
Transplantation. J Heart Lung Transplant. 1993 Sep-Oct;12(5):713-6.
Cooper JD, Patterson GA, Grossman R, Maurer J. Double-lung transplant for advanced chronic 
obstructive lung disease. Am Rev Respir Dis. 1989 Feb;139(2):303-7.
Cooper JE, Gralla J, Chan L, Wiseman AC. Clinical signifi cance of post kidney transplant de novo 
DSA in otherwise stable graft s. Clin Transpl. 2011:359-64.
Copeland CA, Vock DM, Pieper K, Mark DB, Palmer SM. Impact of lung transplantation on recipient 
quality of life: a serial, prospective, multicenter analysis through the fi rst posttransplant year. Chest. 
2013 Mar;143(3):744-50.
Couetil JP, Tolan MJ, Loulmet DF, Guinvarch A, Chevalier PG, Achkar A, Birmbaum P, Carpentier 
AF. Pulmonary bipartitioning and lobar transplantation: a new approach to donor organ shortage. J 
Th orac Cardiovasc Surg. 1997 Mar;113(3):529-37.
Cramer T, Yamanishi Y, Clausen BE, Förster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr 
M, Nizet V, Firestein GS, Gerber HP, Ferrara N, Johnson RS. HIF-1alpha is essential for myeloid 
cell-mediated infl ammation. Cell. 2003 Mar 7;112(5):645-57.
Cypel M, Yeung JC, Liu M, Anraku M, Chen F, Karolak W, Sato M, Laratta J, Azad S, Madonik M, 
Chow CW, Chaparro C, Hutcheon M, Singer LG, Slutsky AS, Yasufuku K, de Perrot M, Pierre AF, 
Waddell TK, Keshavjee S. Normothermic ex vivo lung perfusion in clinical lung transplantation. N 
Engl J Med. 2011 Apr 14;364(15):1431-40.
Damman J, Daha MR, van Son WJ, Leuvenink HG, Ploeg RJ, Seelen MA. Crosstalk between 
complement and Toll-like receptor activation in relation to donor brain death and renal ischemia-
reperfusion injury. Am J Transplant. 2011 Apr;11(4):660-9. Review.
Daud SA, Yusen RD, Meyers BF, Chakinala MM, Walter MJ, Aloush AA, Patterson GA, Trulock EP, 
Hachem RR. Impact of immediate primary lung allograft  dysfunction on bronchiolitis obliterans 
syndrome. Am J Respir Crit Care Med. 2007 Mar 1;175(5):507-13.
Diamond DA, Michalski JM, Lynch JP, Trulock EP 3rd. Effi  cacy of total lymphoid irradiation for 
chronic allograft  rejection following bilateral lung transplantation. Int J Radiat Oncol Biol Phys. 
1998 Jul 1;41(4):795-800.
Dijke IE, Velthuis JH, Caliskan K, Korevaar SS, Maat AP, Zondervan PE, Balk AH, Weimar W, Baan 
CC. Intragraft  FOXP3 mRNA expression refl ects antidonor immune reactivity in cardiac allograft  
patients. Transplantation. 2007 Jun 15;83(11):1477-84.
Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo DG, Coussens LM, Karin M, 
Goldrath AW, Johnson RS. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses 
T-cell function and promotes tumor progression. Cancer Res. 2010 Oct 1;70(19):7465-75.
Eltzschig HK, Carmeliet P. Hypoxia and infl ammation. N Engl J Med. 2011 Feb 17;364(7):656-65. 
Review.
Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. Stroke protection by 
3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide 
synthase. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8880-5.
References
52
Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, Mallory GB, Snell GI, Yousem S. 
Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung 
Transplant. 2002 Mar;21(3):297-310.
Farrar CA, Kupiec-Weglinski JW, Sacks SH. Th e innate immune system and transplantation. Cold 
Spring Harb Perspect Med. 2013 Oct 1;3(10):a015479. Review.
Farrar CA, Zhou W, Lin T, Sacks SH. Local extravascular pool of C3 is a determinant of postischemic 
acute renal failure. FASEB J. 2006 Feb;20(2):217-26.
Fiser SM, Tribble CG, Long SM, Kaza AK, Kern JA, Jones DR, Robbins MK, Kron IL. Ischemia-
reperfusion injury aft er lung transplantation increases risk of late bronchiolitis obliterans syndrome. 
Ann Th orac Surg. 2002 Apr;73(4):1041-7.
Gabbay E, Walters EH, Orsida B, Whitford H, Ward C, Kotsimbos TC, Snell GI, Williams TJ.  Post-
lung transplant bronchiolitis obliterans syndrome (BOS) is characterized by increased exhaled 
nitric oxide levels and epithelial inducible nitric oxide synthase. Am J Respir Crit Care Med. 
2000;162:2182-2187.
Girnita AL, McCurry KR, Iacono AT, Duquesnoy R, Corcoran TE, Awad M, Spichty KJ, Yousem 
SA, Burckart G, Dauber JH, Griffi  th BP, Zeevi A. HLA-specifi c antibodies are associated with 
high-grade and persistent-recurrent lung allograft  acute rejection. J Heart Lung Transplant. 2004 
Oct;23(10):1135-41.
Glanville AR. Antibody-mediated rejection in lung transplantation: myth or reality? J Heart Lung 
Transplant. 2010 Apr;29(4):395-400.
Glanville AR, Aboyoun CL, Havryk A, Plit M, Rainer S, Malouf MA. Severity of lymphocytic 
bronchiolitis predicts long-term outcome aft er lung transplantation. Am J Respir Crit Care Med. 
2008 May 1;177(9):1033-40.
Grossman EJ, Shilling  RA. Bronchiolitis obliterans in lung transplantation: the good, the bad, and the 
future. Transl Res. 2009 Apr;153(4):153-65.
Haendeler J, Hoff mann J, Tischler V, Berk BC, Zeiher AM, Dimmeler S. Redox regulatory and 
anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69. Nat Cell Biol. 
2002;4:743-749.
Hardy JD, Webb WR, Dalton Jr. ML and Walker Jr. GR. Lung homotransplantations in man. JAMA 
1963, 186:1065-1074
Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997 
Nov 1;100(9):2153-7.
Hele DJ, Yacoub MH, Belvisi MG. Th e heterotopic tracheal allograft  as an animal model of obliterative 
bronchiolitis. Respir Res 2001;2:169-83.
Henke JA, Golden JA, Yelin EH, Keith FA, Blanc PD. Persistent increases of BAL neutrophils as a 
predictor of mortality following lung transplant. Chest. 1999 Feb;115(2):403-9.
Hertz MI, Jessurun J, King MB, Savik SK, Murray JJ. Reproduction of the obliterative bronchiolitis 
lesion aft er heterotopic transplantation of mouse airways. Am J Pathol. 1993 Jun;142(6):1945-51.
Higenbottam T, Otulana BA, Wallwork J.Transplantation of the lung. Eur Respir J. 1990 May;3(5):594-
605. Review.
Hirschburger M, Greschus S, Kuchenbuch T, Plötz C, Obert M, Traupe H, Padberg W, Grau V. Lung 
transplantation in the Fischer 344-->Wistar Kyoto rat strain combination is not suitable to study 
bronchiolitis obliterans. J Heart Lung Transplant. 2007 Apr;26(4):390-8.
References
53
Hollmen M, Tikkanen JM, Nykanen AI, Koskinen PK, Lemstrom KB. Tacrolimus treatment eff ectively 
inhibits progression of obliterative airway disease even at later stages of disease development. J 
Heart Lung Transplant. 2008;27:856-864.
Hopkins PM, Aboyoun CL, Chhajed PN, Malouf MA, Plit ML, Rainer SP, Glanville AR. Association 
of minimal rejection in lung transplant recipients with obliterative bronchiolitis.  Am J Respir Crit 
Care Med. 2004 Nov 1;170(9):1022-6.
Huang X, Reichenspurner H, Shorthouse R, Cao W, Berry G, Morris R. Heterotopic tracheal allograft  
transplantation: a new model to study the molecular events causing obliterative airway disease 
(OAD) in rats. J Heart Lung Transplant 1995; 14:S49.
Ikonen T, Kivisaari L, Harjula AL, Lehtola A, Heikkilä L, Kinnula VL, Kyösola K, Savola J, Sipponen 
J, Verkkala K, Mattila SP. Value of high-resolution computed tomography in routine evaluation of 
lung transplantation recipients during development of bronchiolitis obliterans syndrome. J Heart 
Lung Transplant. 1996 Jun;15(6):587-95.
Illigens BM, Yamada A, Anosova N, Dong VM, Sayegh MH, Benichou G. Dual eff ects of the 
alloresponse by Th 1 and Th 2 cells on acute and chronic rejection of allotransplants. Eur J Immunol. 
2009 Nov;39(11):3000-9.
Imtiyaz HZ, Simon MC. Hypoxia-inducible factors as essential regulators of infl ammation. Curr Top 
Microbiol Immunol. 2010;345:105-20. Review.
Ingemansson R, Eyjolfsson A, Mared L, Pierre L, Algotsson L, Ekmehag B, Gustafsson R, Johnsson P, 
Koul B, Lindstedt S, Lührs C, Sjöberg T, Steen S. Clinical transplantation of initially rejected donor 
lungs aft er reconditioning ex vivo. Ann Th orac Surg. 2009 Jan;87(1):255-60. 
Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, 
Mukherji M, Schofi eld CJ, Maxwell PH, Pugh CW, Ratcliff e PJ. Targeting of HIF-alpha to the von 
Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001 Apr 
20;292(5516):468-72.
Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216. 
Review.
Jaramillo A, Smith MA, Phelan D, Sundaresan S, Trulock EP, Lynch JP, Cooper JD, Patterson GA, 
Mohanakumar T. Development of ELISA-detected anti-HLA antibodies precedes the development 
of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function 
aft er lung transplantation. Transplantation. 1999 Apr 27;67(8):1155-61.
Jiang X, Khan MA, Tian W, Beilke J, Natarajan R, Kosek J, Yoder MC, Semenza GL, Nicolls 
MR. Adenovirus-mediated HIF-1α gene transfer promotes repair of mouse airway allograft 
microvasculature and attenuates chronic rejection. J Clin Invest. 2011 Jun;121(6):2336-49.
Johnson BA, Iacono AT, Zeevi A, McCurry KR, Duncan SR. Statin use is associated with improved 
function and survival of lung allograft s. Am J Respir Crit Care Med. 2003 May 1;167(9):1271-8.
Jones ND, Carvalho-Gaspar M, Luo S, Brook MO, Martin L, Wood KJ. Eff ector and memory CD8+ 
T cells can be generated in response to alloantigen independently of CD4+ T cell help. J Immunol. 
2006 Feb 15;176(4):2316-23.
de Jong PA, Dodd JD, Coxson HO, Storness-Bliss C, Paré PD, Mayo JR, Levy RD. Bronchiolitis 
obliterans following lung transplantation: early detection using computed tomographic scanning. 
Th orax. 2006 Sep;61(9):799-804. 
de Jongste JC. Yes to NO: the fi rst studies on exhaled nitric oxide-driven asthma treatment. Eur Respir 
J. 2005;26:379-381.
Kallio EA, Koskinen PK, Aavik E, Vaali K, Lemstom KB. Role of nitric oxide in experimental 
obliterative bronchiolitis (chronic rejection) in the rat. J Clin Invest. 1997;100:2984-2994.
References
54
Kapitsinou PP, Haase VH. Th e VHL tumor suppressor and HIF: insights from genetic studies in mice. 
Cell Death Diff er. 2008 Apr;15(4):650-9. 
Keshavjee SH, Yamazaki F, Cardoso PF, McRitchie DI, Patterson GA, Cooper JD. A method for safe 
twelve-hour pulmonary preservation. J Th orac Cardiovasc Surg. 1989 Oct;98(4):529-34.
Khalifah AP, Hachem RR, Chakinala MM, Schechtman KB, Patterson GA, Schuster DP, Mohanakumar 
T, Trulock EP, Walter MJ. Respiratory viral infections are a distinct risk for bronchiolitis obliterans 
syndrome and death. Am J Respir Crit Care Med. 2004 Jul 15;170(2):181-7.
King BJ, Iyer H, Leidi AA, Carby MR. Gastroesophageal refl ux in bronchiolitis obliterans syndrome: a 
new perspective. J Heart Lung Transplant. 2009 Sep;28(9):870-5.
King MB, Jessurun J, Savik SK, Murray JJ, Hertz MI. Cyclosporine reduces development of obliterative 
bronchiolitis in a murine heterotopic airway model. Transplantation. 1997 Feb 27;63(4):528-32.
Koh KK. Eff ects of statins on vascular wall: vasomotor function, infl ammation, and plaque stability. 
Cardiovasc Res. 2000 Sep;47(4):648-57. Review.
Korom S, Boehler A, Weder W. Immunosuppressive therapy in lung transplantation: state of the art. 
Eur J Cardiothorac Surg. 2009 Jun;35(6):1045-55.
Koskinen PK, Kallio EA, Krebs R, Lemström KB. A dose-dependent inhibitory eff ect of cyclosporine 
A on obliterative bronchiolitis of rat tracheal allograft s. Am J Respir Crit Care Med. 1997 
Jan;155(1):303-12.
Kramer MR, Stoehr C, Whang JL, Berry GJ, Sibley R, Marshall SE, Patterson GM, Starnes VA, 
Th eodore J. Th e diagnosis of obliterative bronchiolitis aft er heart-lung and lung transplantation: 
low yield of transbronchial lung biopsy. J Heart Lung Transplant. 1993 Jul-Aug;12(4):675-81.
Kreisel D, Nava RG, Li W, Zinselmeyer BH, Wang B, Lai J, Pless R, Gelman AE, Krupnick AS, Miller 
MJ. In vivo two-photon imaging reveals monocyte-dependent neutrophil extravasation during 
pulmonary infl ammation. Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):18073-8.
Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Up-regulation of hypoxia-inducible factors 
hif-1alpha and hif-2alpha under normoxic conditions in renal carcinoma cells by von hippel-lindau 
tumor suppressor gene loss of function. Oncogene 2000;19:5435-5443.
Kumar D, Erdman D, Keshavjee S, Peret T, Tellier R, Hadjiliadis D, Johnson G, Ayers M, Siegal D, 
Humar A. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans 
aft er lung transplant. Am J Transplant. 2005 Aug;5(8):2031-6.
Land WG. Innate immunity-mediated allograft  rejection and strategies to prevent it. Transplant Proc. 
2007 Apr;39(3):667-72.
Langenbach SY, Zheng L, McWilliams T, Levvey B, Orsida B, Bailey M, Williams TJ, Snell GI. 
Airway vascular changes aft er lung transplant: potential contribution to the pathophysiology of 
bronchiolitis obliterans syndrome. J Heart Lung Transplant. 2005 Oct;24(10):1550-6.
Laufs U, Endres M, Custodis F, Gertz K, Nickenig G, Liao JK, Bohm M. Suppression of endothelial 
nitric oxide production aft er withdrawal of statin treatment is mediated by negative feedback 
regulation of rho GTPase gene transcription. Circulation. 2000;102:3104-3110.
Laufs U, Liao JK. Direct vascular eff ects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med. 
2000 May;10(4):143-8.
Lee TS, Chang CC, Zhu Y, Shyy JY. Simvastatin induces heme oxygenase-1: a novel mechanism of 
vessel protection. Circulation. 2004 Sep 7;110(10):1296-302.
Lee JH, Lee DS, Kim EK, Choe KH, Oh YM, Shim TS, Kim SE, Lee YS, Lee SD. Simvastatin inhibits 
cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit 
Care Med. 2005 Oct 15;172(8):987-93.
References
55
Lehmann M, Graser E, Risch K, Hancock WW, Müller A, Kuttler B, Hahn HJ, Kupiec-Weglinski 
JW, Brock J, Volk HD. Anti-CD4 monoclonal antibody-induced allograft  tolerance in rats despite 
persistence of donor-reactive T cells. Transplantation. 1997 Oct 27;64(8):1181-7.
Li Y, Köster T, Mörike C, v Hörsten S, Martin U, Bader M, Haverich A, Simon AR. Pravastatin 
prolongs graft  survival in an allogeneic rat model of orthotopic single lung transplantation. Eur J 
Cardiothorac Surg. 2006 Sep;30(3):515-24. 
Li M, Matsunaga N, Hazeki K, Nakamura K, Takashima K, Seya T, Hazeki O, Kitazaki T, Iizawa Y. 
A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fl uorophenyl)sulfamoyl]cyclohex-1-
ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production 
through suppression of intracellular signaling. Mol Pharmacol. 2006 Apr;69(4):1288-95. 
Lim SW, Li C, Ahn KO, Kim J, Moon IS, Ahn C, Lee JR, Yang CW. Cyclosporine-induced renal injury 
induces toll-like receptor and maturation of dendritic cells. Transplantation. 2005 Sep 15;80(5):691-
9.
Linfert D, Chowdhry T, Rabb H. Lymphocytes and ischemia-reperfusion injury. Transplant Rev 
(Orlando). 2009 Jan;23(1):1-10. 
Liu G, Zhao Y. Toll-like receptors and immune regulation: their direct and indirect modulation on 
regulatory CD4+ CD25+ T cells. Immunology. 2007 Oct;122(2):149-56. Review.
Liu JN, Suh DH, Yang EM, Lee SI, Park HS, Shin YS. Attenuation of airway infl ammation by 
simvastatin and the implications for asthma treatment: is the jury still out? Exp Mol Med. 2014 Sep 
12;46:e113.
Long E, Wood KJ. Regulatory T cells in transplantation: transferring mouse studies to the clinic. 
Transplantation. 2009 Nov 15;88(9):1050-6. 
Lu KC, Jaramillo A, Lecha RL, Schuessler RB, Aloush A, Trulock EP, Mendeloff  EN, Huddleston 
CB, Alexander Patterson G, Mohanakumar T. Interleukin-6 and interferon-gamma gene 
polymorphisms in the development of bronchiolitis obliterans syndrome aft er lung transplantation. 
Transplantation. 2002 Nov 15;74(9):1297-302.
Luckraz H, Goddard M, McNeil K, Atkinson C, Sharples LD, Wallwork J. Is obliterative bronchiolitis 
in lung transplantation associated with microvascular damage to small airways? Ann Th orac Surg. 
2006 Oct;82(4):1212-8.
Machuzak M, Santacruz JF, Gildea T, Murthy SC. Airway complications aft er lung transplantation. 
Th orac Surg Clin. 2015;25(1):55-75
Machuzak  M, Santacruz JF, Gildea T, Murthy SC. Airway complications aft er lung transplantation. 
Th orac Surg Clin. 2015;25(1):55-75.
Mason DP, Th uita L, Alster JM, Murthy SC, Budev MM, Mehta AC, Pettersson GB, Blackstone EH. 
Should lung transplantation be performed using donation aft er cardiac death? Th e United States 
experience. Th orac Cardiovasc Surg. 2008 Oct;136(4):1061-6. 
Matsumura Y, Marchevsky A, Zuo XJ, Kass RM, Matloff  JM, Jordan SC. Assessment of pathological 
changes associated with chronic allograft  rejection and tolerance in two experimental models of rat 
lung transplantation. Transplantation. 1995 Jun 15;59(11):1509-17.
McDyer JF. Human and murine obliterative bronchiolitis in transplant. Proc Am Th orac Soc. 2007 
Jan;4(1):37-43.
McKay A, Leung BP, McInnes IB, Th omson NC, Liew FY. A novel anti-infl ammatory role of 
simvastatin in a murine model of allergic asthma. J Immunol. 2004 Mar 1;172(5):2903-8.
References
56
Meyer KC, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC, Brozek J, Glanville AR; 
ISHLT/ATS/ERS BOS Task Force Committee; ISHLT/ATS/ERS BOS Task Force Committee. 
An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of 
bronchiolitis obliterans syndrome. Eur Respir J. 2014 Dec;44(6):1479-503
Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein 
signals activation of adaptive immunity. Nature. 1997 Jul 24;388(6640):394-7.
Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009 Aug 
27;361(9):888-98.
Morita K, Miura M, Paolone DR, Engeman TM, Kapoor A, Remick DG, Fairchild RL. Early 
chemokine cascades in murine cardiac graft s regulate T cell recruitment and progression of acute 
allograft  rejection. J Immunol. 2001 Sep 1;167(5):2979-84.
Morrell MR, Patterson GA, Trulock EP, Hachem RR. Acute antibody-mediated rejection aft er lung 
transplantation. J Heart Lung Transplant. 2009 Jan;28(1):96-100
Murata T, Kinoshita K, Hori M, Kuwahara M, Tsubone H, Karaki H, Ozaki H. Statin protects 
endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler 
Th romb Vasc Biol. 2005;25:2335-2342.
Murphy DM, Forrest IA, Corris PA, Johnson GE, Small T, Jones D, Fisher AJ, Egan JJ, Cawston TE, 
Ward C, Lordan JL. Simvastatin attenuates release of neutrophilic and remodeling factors from 
primary bronchial epithelial cells derived from stable lung transplant recipients. Am J Physiol Lung 
Cell Mol Physiol. 2008 Mar;294(3):L592-9. 
Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, Lee JB, Hartono C, Li B, Sharma VK, 
Seshan SV, Kapur S, Hancock WW, Schwartz JE, Suthanthiran M. Messenger RNA for FOXP3 in 
the urine of renal-allograft  recipients. N Engl J Med. 2005 Dec 1;353(22):2342-51.
Neuringer IP, Aris RM, Burns KA, Bartolotta TL, Chalermskulrat W, Randell SH. Epithelial kinetics 
in mouse heterotopic tracheal allograft s. Am J Transplant 2002;2:410-419.
Nizet V, Johnson RS. Interdependence of hypoxic and innate immune responses. Nat Rev Immunol 
2009;9:609-617.
Okazaki M, Krupnick AS, Kornfeld CG, Lai JM, Ritter JH, Richardson SB, Huang HJ, Das NA, 
Patterson GA, Gelman AE, Kreisel D. A mouse model of orthotopic vascularized aerated lung 
transplantation. Am J Transplant. 2007 Jun;7(6):1672-9.
Osaki S, Maloney JD, Meyer KC, Cornwell RD, Edwards NM, De Oliveira NC. Th e impact of the 
lung allocation scoring system at the single national Veterans Aff airs Hospital lung transplantation 
program. Eur J Cardiothorac Surg. 2009 Sep;36(3):497-501.
Palmer SM, Burch LH, Davis RD, Herczyk WF, Howell DN, Reinsmoen NL, Schwartz DA. Th e role of 
innate immunity in acute allograft  rejection aft er lung transplantation. Am J Respir Crit Care Med. 
2003 Sep 15;168(6):628-32. Epub 2003 May 28.
Palmer SM, Davis RD, Hadjiliadis D, Hertz MI, Howell DN, Ward FE, Savik K, Reinsmoen 
NL. Development of an antibody specifi c to major histocompatibility antigens detectable by 
fl ow cytometry aft er lung transplant is associated with bronchiolitis obliterans syndrome.
Transplantation. 2002 Sep 27;74(6):799-804.
de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir 
Crit Care Med. 2003 Feb 15;167(4):490-511.
Poitz DM, Augstein A, Hesse K et al. Regulation of the hif-system in human macrophages--diff erential 
regulation of hif-alpha subunits under sustained hypoxia. Molecular immunology 2014;57:226-235.
References
57
Prabhakar NR, Semenza GL. Adaptive and maladaptive cardiorespiratory responses to continuous 
and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiol Rev 2012;92:967-
1003.
Pratt JR, Abe K, Miyazaki M, Zhou W, Sacks SH. In situ localization of C3 synthesis in experimental 
acute renal allograft  rejection. Am J Pathol. 2000 Sep;157(3):825-31.
Puri V, Patterson GA. Adult lung transplantation: technical considerations. Semin Th orac Cardiovasc 
Surg. 2008 Summer;20(2):152-64. 
Ravetch JV, Lanier LL. Immune inhibitory receptors. Science. 2000 Oct 6;290(5489):84-9.
Reichenspurner H, Girgis RE, Robbins RC, Yun KL, Nitschke M, Berry GJ, Morris RE, Th eodore 
J, Reitz BA. Stanford experience with obliterative bronchiolitis aft er lung and heart-lung 
transplantation. Ann Th orac Surg. 1996 Nov;62(5):1467-72.
Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG, 
Karin M. NF-kappaB links innate immunity to the hypoxic response through transcriptional 
regulation of HIF-1alpha. Nature. 2008 Jun 5;453(7196):807-11. 
Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, Smith KD, Hood LE, Aderem A. Th e evolution 
of vertebrate Toll-like receptors. Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9577-82. 
Robertson AG, Griffi  n SM, Murphy DM, Pearson JP, Forrest IA, Dark JH, Corris PA, Ward C. 
Targeting allograft  injury and infl ammation in the management of post-lung transplant bronchiolitis 
obliterans syndrome. Am J Transplant. 2009 Jun;9(6):1272-8. 
Rocha PN, Plumb TJ, Crowley SD, Coff man TM. Eff ector mechanisms in transplant rejection. 
Immunol Rev. 2003 Dec;196:51-64. Review.
Rogers NJ, Lechler RI. Allorecognition. Am J Transplant. 2001 Jul;1(2):97-102. Review.
Rostron AJ, Cork DM, Avlonitis VS, Fisher AJ, Dark JH, Kirby JA. Contribution of Toll-like receptor 
activation to lung damage aft er donor brain death. Transplantation. 2010 Oct 15;90(7):732-9.
Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, Treuting P, Siewe L, Roers A, Henderson 
WR Jr, Muller W, Rudensky AY. Regulatory T cell-derived interleukin-10 limits infl ammation at 
environmental interfaces. Immunity. 2008 Apr;28(4):546-58.
Safavi S, Robinson DR, Soresi S, Carby M, Smith JD. De novo donor HLA-specifi c antibodies 
predict development of bronchiolitis obliterans syndrome aft er lung transplantation. J Heart Lung 
Transplant. 2014 Dec;33(12):1273-81.
Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the 
ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on 
redox-induced changes. J Biol Chem. 1997 Sep 5;272(36):22642-7.
Sato M, Keshavjee S, Liu M. Translational research: animal models of obliterative bronchiolitis aft er 
lung transplantation. Am J Transplant 2009;9:1981-7.
Sato M, Waddell TK, Wagnetz U, Roberts HC, Hwang DM, Haroon A, Wagnetz D, Chaparro C, Singer 
LG, Hutcheon MA, Keshavjee S. Restrictive allograft  syndrome (RAS): a novel form of chronic lung 
allograft  dysfunction. J Heart Lung Transplant. 2011 Jul;30(7):735-42.
Sato M. Chronic lung allograft  dysfunction aft er lung transplantation: the moving target. Gen Th orac 
Cardiovasc Surg. 2013 Feb;61(2):67-78. 
Scholma J, Slebos DJ, Boezen HM, van den Berg JW, van der Bij W, de Boer WJ, Koëter GH, 
Timens W, Kauff man HF, Postma DS. Eosinophilic granulocytes and interleukin-6 level in 
bronchoalveolar lavage fl uid are associated with the development of obliterative bronchiolitis aft er 
lung transplantation. Am J Respir Crit Care Med. 2000 Dec;162(6):2221-5.
References
58
Semenza GL. Surviving ischemia. Adaptive responses mediated by hypoxia-inducible factor 1. J Clin 
Invest 2000;106:809-812.
Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an 
enhancer element located 3’ to the human erythropoietin gene. Proc Natl Acad Sci U S A. 1991 Jul 
1;88(13):5680-4.
Singer JP, Chen J, Blanc PD, Leard LE, Kukreja J, Chen H. A thematic analysis of quality of life in 
lung transplant: the existing evidence and implications for future directions. Am J Transplant. 2013 
Apr;13(4):839-50. 
Slovis BS, Loyd JE, King LE Jr. Photopheresis for chronic rejection of lung allograft s. N Engl J Med. 
1995 Apr 6;332(14):962.
Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through 
toll-like receptor 4. J Immunol. 2001 Sep 1;167(5):2887-94.
Stewart S, Fishbein MC, Snell GI, Berry GJ, Boehler A, Burke MM, Glanville A, Gould FK, Magro 
C, Marboe CC, McNeil KD, Reed EF, Reinsmoen NL, Scott JP, Studer SM, Tazelaar HD, Wallwork 
JL, Westall G, Zamora MR, Zeevi A, Yousem SA. Revision of the 1996 working formulation for the 
standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant. 2007 
Dec;26(12):1229-42
Stinn JL, Taylor MK, Becker G, Nagano H, Hasegawa S, Furakawa Y, Shimizu K, Libby P, Mitchell RN. 
Interferon-gamma-secreting T-cell populations in rejecting murine cardiac allograft s: assessment 
by fl ow cytometry. Am J Pathol. 1998 Nov;153(5):1383-92.
Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature. 2009 Jan 
29;457(7229):557-61.
Swanson SJ, Mentzer SJ, Reilly JJ, Bueno R, Lukanich JM, Jaklitsch MT, Kobzik L, Ingenito EP, 
Fuhlbrigge A, Donovan C, McKee C, Boyle K, Fagan GP, Sugarbaker DJ. Surveillance transbronchial 
lung biopsies: implication for survival aft er lung transplantation. J Th orac Cardiovasc Surg. 2000 
Jan;119(1):27-37.
Takeda K, Akira S. TLR signaling pathways. Semin Immunol. 2004 Feb;16(1):3-9.
Takemoto SK, Zeevi A, Feng S, Colvin RB, Jordan S, Kobashigawa J, Kupiec-Weglinski J, Matas A, 
Montgomery RA, Nickerson P, Platt JL, Rabb H, Th istlethwaite R, Tyan D, Delmonico FL. National 
conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant. 
2004 Jul;4(7):1033-41.
Tarlinton DM, Batista F, Smith KG. Th e B-cell response to protein antigens in immunity and 
transplantation. Transplantation. 2008 Jun 27;85(12): 1698-704. 
Th abut G, Vinatier I, Brugière O, Lesèche G, Loirat P, Bisson A, Marty J, Fournier M, Mal H. Infl uence 
of preservation solution on early graft  failure in clinical lung transplantation. Am J Respir Crit Care 
Med. 2001 Oct 1;164(7):1204-8.
Th ompson AA, Elks PM, Marriott HM et al. Hypoxia-inducible factor 2alpha regulates key neutrophil 
functions in humans, mice, and zebrafi sh. Blood 2014;123:366-376.
Trulock EP, Christie JD, Edwards LB, Boucek MM, Aurora P, Taylor DO, Dobbels F, Rahmel AO, Keck 
BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty-
fourth offi  cial adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant. 
2007 Aug;26(8):782-95. 
Tuuminen R, Syrjälä S, Krebs R, Keränen MA, Koli K, Abo-Ramadan U, Neuvonen PJ, Tikkanen JM, 
Nykänen AI, Lemström KB. Donor simvastatin treatment abolishes rat cardiac allograft  ischemia/
reperfusion injury and chronic rejection through microvascular protection. Circulation. 2011 Sep 
6;124(10):1138-50.
References
59
Tuuminen R, Nykänen AI, Saharinen P, Gautam P, Keränen MA, Arnaudova R, Rouvinen E, Helin 
H, Tammi R, Rilla K, Krebs R, Lemström KB. Donor simvastatin treatment prevents ischemia-
reperfusion and acute kidney injury by preserving microvascular barrier function. Am J Transplant. 
2013 Aug;13(8):2019-34.
Valentine VG, Robbins RC, Berry GJ, Patel HR, Reichenspurner H, Reitz BA, Th eodore J. Actuarial 
survival of heart-lung and bilateral sequential lung transplant recipients with obliterative 
bronchiolitis. J Heart Lung Transplant. 1996 Apr;15(4):371-83.
Valenza F, Rosso L, Coppola S, Froio S, Palleschi A, Tosi D, Mendogni P, Salice V, Ruggeri GM, 
Fumagalli J, Villa A, Nosotti M, Santambrogio L, Gattinoni L. Ex vivo lung perfusion to improve 
donor lung function and increase the number of organs available for transplantation. Transpl Int. 
2014 Jun;27(6):553-61.
Verleden GM, Fisher AJ, Boehler A and Estenne M. Bronchiolitis obliterans syndrome. In: Fisher AJ, 
Verleden GM, Massard G (eds) Lung transplantation: European Respiratory Society monograph. 
Sheffi  eld: ERS, 2009, pp.197–206.
Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classifi cation system for chronic 
lung allograft  dysfunction. J Heart Lung Transplant. 2014 Feb;33(2):127-33.
Verleden GM, Dupont LJ, Van Raemdonck DE, Vos R, Vanaudenaerde BM; Leuven Lung Transplant 
Group. Lung transplantation: a 15-year single-center experience. Clin Transpl. 2007:121-30. 
Verleden SE, Vandermeulen E, Ruttens D, Vos R, Vaneylen A, Dupont LJ, Van Raemdonck DE, 
Vanaudenaerde BM, Verleden GM. Neutrophilic reversible allograft  dysfunction (NRAD) and 
restrictive allograft  syndrome (RAS). Semin Respir Crit Care Med. 2013 Jun;34(3):352-60. 
Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. 
Innate or adaptive immunity? Th e example of natural killer cells. Science. 2011 Jan 7;331(6013):44-
9.
Walker WE, Nasr IW, Camirand G, Tesar BM, Booth CJ, Goldstein DR. Absence of innate MyD88 
signaling promotes inducible allograft  acceptance. J Immunol. 2006 Oct 15;177(8):5307-16.
Wang CY, Liu PY, Liao JK. Pleiotropic eff ects of statin therapy: molecular mechanisms and clinical 
results. Trends Mol Med 2008;14:37-44.
Wang JQ, Jeelall YS, Ferguson LL, Horikawa K. Toll-Like Receptors and Cancer: MYD88 Mutation 
and Infl ammation. Front Immunol. 2014 Jul 31;5:367. 
Watts KL, Sampson EM, Schultz GS, Spiteri MA. Simvastatin inhibits growth factor expression and 
modulates profi brogenic markers in lung fi broblasts. Am J Respir Cell Mol Biol. 2005 Apr;32(4):290-
300. Epub 2005 Jan 27.
Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, Lederer DJ, Mulligan MJ, Patterson 
GA, Singer LG, Snell GI, Verleden GM, Zamora MR, Glanville AR. A consensus document for 
the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation 
Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 
2015 Jan;34(1):1-15.
Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, 
Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory 
integrin site. Nat Med. 2001 Jun;7(6):687-92.
Whitelegg A, Barber LD. Th e structural basis of T-cell allorecognition.Tissue Antigens. 2004 
Feb;63(2):101-8. Review.
Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol. 2012 
May 25;12(6):417-30. Review.
References
60
Wood KJ, Goto R. Mechanisms of rejection: current perspectives. Transplantation. 2012 Jan 
15;93(1):1-10. Review.
Woodrow JP, Shlobin OA, Barnett SD, Burton N, Nathan SD.Comparison of bronchiolitis obliterans 
syndrome to other forms of chronic lung allograft  dysfunction aft er lung transplantation.J Heart 
Lung Transplant. 2010 Oct;29(10):1159-64. 
Wynn TA. T(H)-17: a giant step from T(H)1 and T(H)2. Nat Immunol. 2005 Nov;6(11):1069-70
Yang H, Minamishima YA, Yan Q, Schlisio S, Ebert BL, Zhang X, Zhang L, Kim WY, Olumi AF, Kaelin 
WG Jr. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB 
agonist Card9 by CK2. Mol Cell. 2007 Oct 12;28(1):15-27.
Yousem SA, Berry GJ, Cagle PT, Chamberlain D, Husain AN, Hruban RH, Marchevsky A, Ohori NP, 
Ritter J, Stewart S, Tazelaar HD. Revision of the 1990 working formulation for the classifi cation of 
pulmonary allograft  rejection: Lung Rejection Study Group. J Heart Lung Transplant. 1996 Jan;15(1 
Pt 1):1-15.
Yousem SA, Dauber JA, Keenan R, Paradis IL, Zeevi A, Griffi  th BP. Does histologic acute rejection 
in lung allograft s predict the development of bronchiolitis obliterans? Transplantation. 1991 
Aug;52(2):306-9.
Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological signifi cance. J Cell 
Mol Med. 2010 Nov;14(11):2592-603. 
Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H. HMGB1 
signals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006 Aug;26(2):174-9.
Yuan X, Paez-Cortez J, Schmitt-Knosalla I, D’Addio F, Mfarrej B, Donnarumma M, Habicht A, 
Clarkson MR, Iacomini J, Glimcher LH, Sayegh MH, Ansari MJ. A novel role of CD4 Th 17 cells in 
mediating cardiac allograft  rejection and vasculopathy. J Exp Med. 2008 Dec 22;205(13):3133-44.
Yusen RD, Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, Kirk 
R, Lund LH, Rahmel AO, Stehlik J; International Society for Heart and Lung Transplantation. 
Th e Registry of the International Society for Heart and Lung Transplantation: Th irtieth Adult 
Lung and Heart-Lung Transplant Report--2013; focus theme: age. J Heart Lung Transplant. 2013 
Oct;32(10):965-78.
Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, Goldfarb SB, Levvey 
BJ, Lund LH, Meiser B, Stehlik J; International Society for Heart and Lung Transplantation. Th e 
registry of the International Society for Heart and Lung Transplantation: thirty-fi rst adult lung and 
heart-lung transplant report--2014; focus theme: retransplantation. J Heart Lung Transplant. 2014 
Oct;33(10):1009-24. 
Zheng L, Walters EH, Ward C, Wang N, Orsida B, Whitford H, Williams TJ, Kotsimbos T, Snell GI.
Airway neutrophilia in stable and bronchiolitis obliterans syndrome patients following lung 
transplantation.Th orax. 2000 Jan;55(1):53-9.
Zuckerbraun BS, Shiva S, Ifedigbo E, Mathier MA, Mollen KP, Rao J, Bauer PM, Choi JJ, Curtis E, 
Choi AM, Gladwin MT. Nitrite potently inhibits hypoxic and infl ammatory pulmonary arterial 
hypertension and smooth muscle proliferation via xanthine oxidoreductase-dependent nitric oxide 
generation. Circulation. 2010 Jan 5;121(1):98-109.
Zych B, García Sáez D, Sabashnikov A, De Robertis F, Amrani M, Bahrami T, Mohite PN, Patil NP, 
Weymann A, Popov AF, Reed A, Carby M, Simon AR. Lung transplantation from donors outside 
standard acceptability criteria - are they really marginal? Transpl Int. 2014 Jul 29.  
References
